First Highly Regio- and Diastereoselective [3+2] Cycloaddition of Chiral Nonracemic Alkenyl Fischer Carbene Complexes with Diazomethane Derivatives: Preparation and Synthetic Applications of Enantiomerically Pure Δ^2 -Pyrazolines

José Barluenga,*^[a] Félix Fernández-Marí,^[a] Argimiro L. Viado,^[a] Enrique Aguilar,^[a] Bernardo Olano,^[a] Santiago García-Granda,^[b] and Carmen Moya-Rubiera^[b]

Abstract: The [3+2] cycloaddition of alkenyl Fischer carbene complexes **1** and **6** with diazomethane derivatives to give Δ^2 -pyrazoline carbenes **2**, **4**, and **7** is described. The conversion of (–)-8-phenylmenthol-derived carbenes **6** into pyrazoline esters **9** through a one-pot cycloaddition – protection – oxidation is presented as an expeditious route to enantiomerically pure 3-alkoxycarbonyl- Δ^2 -pyrazolines in good yields and in a highly regio- and diastereoselective manner. Pyrazolidines **13** were synthesized in excellent overall yields from **9** through pyrazolines **11** and **12**, the

Keywords: amino alcohols • azaprolines • carbene complexes • cycloadditions • pyrazolines diastereoselective reduction of C=N bond being the key step. Azaprolines **16** and **17** were prepared in very good yields from epimeric *trans*-**13** or *cis*-**13** by oxidative deprotection of the silylated hydroxy group. In an alternative reaction, the pyrazolidine ring of **13** was reduced to obtain protected openchain 2,4-diamino alcohols **19** with three chiral centers.

Introduction

During the last three decades since their discovery in 1964,^[1] Fischer carbene complexes have emerged as versatile synthons in organic synthesis.^[2] Thus, thermal cyclopropanations^[3] and Dötz benzannulations^[4] as well as photoinduced reactions^[5] and other cyclizations of diverse topological characteristics^[6] occur on the metal–carbene carbon functionality, whereas the carbene ligand of α , β -unsaturated complexes is usually involved in [2+2]^[7] and [4+2]^[8] cycloadditions.

1,3-Dipolar cycloadditions are a powerful class of reactions for the preparation of functionalized five-membered heterocycles.^[9] In the field of Fischer carbene complexes, the α , β unsaturated derivatives have been scarcely used in [3+2] cycloadditions with 1,3-dipoles, in contrast with other type of

Departamento de Química Física y Analítica (X-ray analysis) Facultad de Química, Julián Clavería 8 Universidad de Oviedo, E-33071 Oviedo (Spain) cycloadditions (vide supra). In this regard, Fischer^[10] reported the first [3+2] cycloaddition of this type between pentacarbonyl(ethoxy)phenylethynyltungsten and diazomethane obtaining the corresponding pyrazole derivative; the process was improved by Wulff and Chan^[11] thirteen years later by the introduction of a bulky trimethylsilyl group on the diazomethane in order to prevent carbene-carbon olefination and thus obtaining pyrazole carbene complexes. More recently, (alkoxy)alkynyl carbenes have been shown to react with nitrones^[12] and masked 1,3-dipoles^[13] to give dihydroisoxazole and pyrrole or pyrazole carbene complexes respectively. On the other hand, only one case of participation of alkenyl Fischer carbenes in 1,3-dipolar cycloadditions has been reported so far,^[14] which involves the reaction of an alkenyl carbene containing an exo-methylene double bond with trimethylsilyldiazomethane (TMSCHN₂) yielding spiropyrazoline derivatives.

There is a large number of Δ^2 -pyrazolines described in the literature^[15] due to their synthetic accessibility and important applications. Thus, Δ^2 -pyrazolines are of interest for their biological activity (for example, as antiinflammatory agents)^[16] and physical applications (for example, as optical brighteners)^[17] as well as for their use as synthons in the preparation of several hetero- and carbocyclic derivatives; hence, procedures to obtain these systems as enantiomerically pure compounds in a regio- and diastereoselective way are of

Chem. Eur. J. 1999, 5, No. 3 © WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1999 0947-6539/99/0503-0883 \$ 17.50+.50/0

- 883

[[]a] Prof. Dr. J. Barluenga, Lic. F. Fernández-Marí, Dr. A. L. Viado, Dr. E. Aguilar, Dr. B. Olano Instituto Universitario de Química Organometálica Enrique Moles – Unidad Asociada al C.S.I.C. Facultad de Química, Julián Clavería 8 Universidad de Oviedo, E-33071 Oviedo (Spain) Fax: (+34) 98-5103-446 E-mail: barluenga@sauron.quimica.uniovi.es
[b] Lic. C. Moya-Rubiera, Dr. S. García-Granda

great value. In this context, we present here the reaction of diazo compounds with alkenyl Fischer carbenes derived from chiral alcohols as an expedient synthesis of enantiomerically pure Δ^2 -pyrazolines; the second part of this paper deals with the transformation of these compounds into several polyfunctionalized cyclic and open-chain derivatives.

Results and Discussion

[3+2] Cycloaddition of Fischer carbene complexes 1 and 6 with diazomethane derivatives: The first experiments were carried out with (\pm) -menthol-derived chromium carbenes 1, which, after treatment with a slight excess of trimethylsilyldiazomethane in THF at room temperature for a few hours, gave Δ^2 -pyrazoline carbene complexes **2** as single regioisomers in moderate yields; compounds 2 were detected as mixtures of diastereomers (diastereomeric ratio $[dr] \leq 3:1$) with relative trans stereochemistry at the pyrazoline ring (Scheme 1, Table 1). The formation of 2 could be rationalized by assuming that the initially formed Δ^1 -pyrazoline **3** undergoes a tautomerization to the thermodynamically more stable Δ^2 -pyrazoline.^[18] Carbene **1d** (R² = Me) was used in order to isolate the initial Δ^1 -pyrazoline cycloadduct; however, only Δ^2 -pyrazoline 4 could be obtained as a mixture of diastereomers (dr = 1:1) after chromatographic purification with silica gel (Scheme 1, Table 1, entry 4). A different compound was primarily formed in the reaction, as indicated by TLC, which should be the silvlated Δ^1 -pyrazoline 5; this cycloadduct would lead to the final Δ^2 -pyrazoline derivative by desilylation during chromatographic work-up.^[19] The structure suggested for compound 4, containing a tetracarbonyl unit, was supported by the observation in the ¹³C NMR spectrum of six signals (two of them are duplicated) at $\delta = 232.1$ (double), 231.1 (double), 220.5, 220.1 and 219.7, and 219.2 that were assigned to the four CO groups belonging to the two diastereomers, as well as two signals at 342.0 and 341.8 assigned to the carbone carbons.

Abstract in Spanish: En este trabajo se describe por primera vez la cicloadición [3+2] de los alcoxi alquenil carbenos de Fischer 1 y 6 con diazocompuestos, que conduce a los correspondientes Δ^2 -pirazolinocarbenos 2, 4 y 7. Se presenta, asimismo, la transformación de los carbenos derivados de (-)-8-fenilmentol 6 en los ésteres pirazolínicos 9, mediante una secuencia one-pot de cicloadición-protección-oxidación, lo que supone una ruta directa para la obtención de alcoxicarbonil- Δ^2 -pirazolinas con buenos rendimientos y de forma altamente regio- y diastereoselectiva. Las pirazolidinas 13 se sintetizaron, con excelentes rendimientos globales, a partir de 9 vía las pirazolinas 11 y 12, siendo el paso clave de la secuencia la reducción diastereoselectiva del doble enlace C=N. Las azaprolinas 16 y 17 se prepararon, con elevados rendimientos, a partir de los epímeros trans-13 o cis-13 mediante desproteción oxidativa del grupo hidroxilo sililado. Por otra parte, el anillo pirazolidínico de los compuestos 13 fue reducido dando lugar a los 2,4-diaminoalcoholes protegidos de cadena abierta 19 que presentan tres centros estereogénicos.



Scheme 1. [3+2] Cycloaddition of (\pm) -menthol-derived Fischer carbenes 1 and trimethylsilyldiazomethane.

Table 1. Synthesis of Δ^2 -pyrazoline complexes **2** and **4**.

Entry	Carbene	\mathbb{R}^1	R ²	Adduct	Time (h)	Yield (%) ^[a]	dr ^[b]
1	1a	Ph	Н	2 a	1	46	3:1
2	1b	2-furyl	Н	2 b	6	38	2:1
3	1c	<i>p</i> -anisyl	Н	2 c	6	40	2:1
4	1 d	Н	Me	4	4	72	1:1

[a] Yield of isolated product after chromatographic purification; diastereomers not separated. [b] Determined by ¹H NMR from crude reaction mixture.

The lowering in the reaction rate observed when an electron-rich substituent is introduced in the carbene structure (Table 1, entry 1 vs. 2 and 3) can be rationalized in terms of the frontier molecular orbital theory, taking into account that the reaction is likely owing to the interaction between the LUMO of carbene complex and the HOMO of the dipole.

In view of the preliminary results and in order to improve the diastereoselectivity of the cycloaddition process, the use of (–)-8-phenylmenthol-derived carbenes **6** was considered, taking into account the excellent results obtained in addition reactions to alkenyl Fischer carbenes bearing this chiral auxiliary.^[20] The reaction of carbenes **6** with several diazomethane derivatives under the conditions mentioned above led in a few hours to the corresponding Δ^2 -pyrazoline carbenes **7** as the only diastereomer (dr > 95:5, by ¹H NMR of crude products) in moderate yields (Scheme 2, Table 2).^[21]

Cycloadducts **7** were transformed into the corresponding *N*-Boc derivatives **8** by treatment with $(Boc)_2O$ at -78 °C. The metal pentacarbonyl moiety was removed from **8** by oxidation with pyridine *N*-oxide (PNO) at room temperature, giving Δ^2 -pyrazoline esters **9** in good yield. The overall yields for the transformation of **6** into **9** were greatly improved by the one-pot procedure without isolation of derivatives **7** and **8** (Table 2, entry 2). On the other hand, pyrazoline esters **9** can also be prepared from the corresponding analogue esters of carbenes; thus, compound **9b** was obtained from *trans*-cinnamate **10** (R¹=Ph) and trimethylsilyldiazomethane but

884 —



10 $R^{*}OH = (-)-8$ -phenylmenthol

Scheme 2. [3+2] Cycloaddition of (-)-8-phenylmenthol-derived Fischer carbenes **6** and diazomethane derivatives.

Table 2. Synthesis of Δ^2 -pyrazoline complexes 7 and 8 and esters 9.

En- try	Car- bene	\mathbb{R}^1	\mathbb{R}^2	7 (%) ^[a]	8 (%) ^[a]	9 (%) ^[a]	6 to 9 One-pot yield (%) ^[a]
1 ^[b]	6a	Ph	Н	a (\approx 29) ^[c]	_	a	79
2	6a	Ph	TMS	b (52)	b (60)	b (75)	73 (23) ^[d] (65) ^[e]
3	6a	Ph	Ph	c (40)	c (61)	c (83)	-
4	6a	Ph	$CH=CH_2$	d (47)	d (69)	d (86)	_
5	6b	2-furyl	TMS	e (53)	$e (\approx 68)^{[c]}$	e	55
6	6b	2-furyl	Ph	f (42)	$f (\approx 65)^{[c]}$	f (79)	-
7	6b	2-furyl	$CH=CH_2$	g (50)	g (72)	g (87)	-
8	6b	2-furyl	Н	-	-	h	74 ^[f]

[a] Yield of isolated product after chromatographic purification. [b] Reaction performed at -78 °C. [c] Compounds not characterized owing to partial oxidation. [d] Overall yield in the stepwise procedure. [e] Yield starting from **10**. [f] dr = 92:8; diastereomers not separated.

at higher temperature (67 °C), longer reaction time (8 days) and with much poorer diastereoselectivity (dr=60:40) (Scheme 2, Table 2, entry 2). These results clearly show the rate and diastereoselectivity enhancement of the metal pentacarbonyl moiety over the oxygen atom in the cycloaddition process.^[22]

The relative *trans* configuration in the Δ^2 -pyrazoline ring of compounds **7–9** was established by ¹H NMR coupling constant analysis^[23] as well as NOE experiments, and the absolute stereochemistry of stereogenic centers, as depicted in Scheme 2, was assigned on the basis of the X-ray analysis of compound **8b** (Figure 1).^[24–25]

The asymmetric induction observed in the [3+2] cycloaddition process can be understood by assuming that in the reactive conformation of **6**, the chiral auxiliary phenyl group shields the double bond (Re,Re)-face by π,π -orbital over-



Figure 1. Crystal structure of 8b.

lapping, inducing the dipole to attack selectively from the (Si,Si)-face (Figure 2).

Synthetic applications of Δ^2 -pyrazoline esters 9: The use of pyrazoline derivatives, synthesized as diazoalkane/olefin cycloadducts, has typically been limited to the preparation of derivatized cyclopropanes or pyrazoles, obtained by nitrogen extrusion^[26] or aromatization^[27] of the initial adduct,



Figure 2. Posited reactive conformation of 6, in which the chiral auxiliary phenyl group shields the (*Re*,*Re*)-face of the doble bond, inducing selective attack from the (*Si*,*Si*)-face.

respectively. However, the structure of 3-alkoxycarbonyl- Δ^2 pyrazolines **9** described in this paper suggests, in principle, their transformation into pyrazolidine-3-carboxylic acid derivatives (azaprolines) and diamino acids or alcohols basically by selective carbon-nitrogen double-bond reduction and further nitrogen – nitrogen single-bond hydrogenolysis. In this sense, several attempts at catalytic hydrogenation (Pd/C, black Pd, PtO₂, Raney Ni, Rh/Al₂O₃) of the C=N bond were unsuccessful; moreover, the presence of an electron-withdrawing group on N1 of **9** makes the use of complex hydrides the method of choice for that purpose.^[27b] Nevertheless, the treatment of Δ^2 -pyrazoline esters **9** with different complex hydrides led always to the reduction of the ester group, the C=N bond remaining intact.^[28] After optimization of the reaction, Δ^2 -pyrazoline carbinols **11** were obtained in very good yields by reduction of **9** with NaBH₄ in THF/MeOH, with almost quantitative recovery of the chiral auxiliary, (–)-8-phenylmenthol, during the work-up (Scheme 3, Table 3).



Scheme 3. Conversion of Δ^2 -pyrazoline esters 9 into pyrazolidine derivatives 13 and bicyclic compounds 14.

Further attempts to reduce the C=N bond of **11** failed, hence we decided to protect the hydroxy functionality to prevent the likely participation of the OH group in the reduction process. The reaction of **11** with *tert*-butyldimethylsilyl chloride (TBDMSCl) using imidazole (Im) as base gave rise to the pyrazoline silyl ethers **12** in quantitative yield.^[29] The best results in the C=N reduction of **12** were achieved by using Superhydride (LiBEt₃H), which furnishes the desired pyrazolidines **13** in excellent yields as a mixture of diastereomers, *cis*-**13** and *trans*-**13**, that could be isolated by chromatographic separation (Scheme 3, Table 3).

The stereochemistry of **13** was assigned based on conventional ¹H and ¹³C NMR data as well as HMBC, HMQC, and NOESY experiments. In this regard the conclusive data for the assignment of the stereochemistry of the new stereogenic

Table 3. Synthesis of Δ^2 -pyrazolines **11** and **12** and pyrazolidines **13**.

center of **13b** and **13d** come from the NOESY spectra of bicyclic derivatives (\pm) -**14b** and (\pm) -**14d**, respectively, obtained by treatment of the pyrazolidine precursors (\pm) -**13** (prepared from (\pm) -menthol derivatives **2** following the same sequence) with benzyl chloroformate (CBZCI) and subsequent reaction with tetrabutylammonium fluoride (TBAF) to promote a tandem desilylation/cyclization process (Scheme 3). Thus, the cross-peak observed between hydrogens on C3 and C5 of the pyrazolidine ring of **14** clearly indicates a *cis* relative stereochemistry, as shown in Scheme 3; the X-ray structure of (\pm) -**14b** corroborates this assignment (Figure 3).^[24,25]



Figure 3. Crystal structure of 14b.

As is listed in Table 3, the *cis*-13 epimer was the only observed isomer in the reduction of the C=N bond of 12a (entry 1) whereas *trans*-13 was exclusively detected when the starting materials were 12b and 12d (entries 2 and 7); only the formation of *cis*-13a can be fully understood considering that the hydride attacks, as expected, from the opposite side to the R¹ substituent. A quick look at the solvent influence (entries 3-5) allows us to conclude that although the polarity and/or the complexing ability of the solvent seem to play a role in the asymmetric induction of the process, this is not drastic or decisive; in this sense, a decrease in the reaction temperature favors, but not strongly, the formation of *trans*-13

	•								
Entry	\mathbb{R}^1	\mathbb{R}^2	$11 \ (\%)^{[a]}$	12 (%) ^[a]	13	Solvent	Т	trans-13/cis-13 ^[b]	Yield $(\%)^{[a,c]}$
1	Ph	Н	a (83)	a (quant.)	a	CH_2Cl_2	-78°C to RT	< 5/95	85
2	Ph	TMS	b (81)	b (quant.)	b	CH_2Cl_2	-78 °C to RT	> 95/5	95
3	Ph	CH=CH ₂	c (quant.)	c (96)	с	THF	RT	1/2	14/28
4					с	hexane	RT	1/1	35/37
5					с	CH_2Cl_2	RT	2/1	52/26
6					с	CH_2Cl_2	-78°C to RT	4.7/1	82/17
7	2-furyl	TMS	d (76)	d (quant.)	d	CH_2Cl_2	$-78^\circ C$ to RT	> 95/5	93

[a] Isolated yields. [b] By ¹H NMR (300 MHz) of crude mixtures. [c] Yields on the left refer to trans-13 and those on the right refer to cis-13.

886 -----

(entry 5 vs. 6). In view of these results and without a deeper study, it can be concluded that the stereochemical course of the reduction, far from being simple, must be influenced by both the reaction conditions (solvent and temperature) and the nature of the substituents R^1 and R^2 , also taking into account that the orientation of the OTBDMS group during the reaction might play an important role in the stereochemical outcome.

Pyrazolidines 13 are fairly unstable and undergo slow oxidation in the air to the starting Δ^2 -pyrazolines 12; hence they must be stored at -20 °C under an inert atmosphere after purification. This prompted us to protect the N2 in 13 prior to oxidation of the silyl ether moiety to the corresponding azaprolines. Compounds 13 were treated with benzyl chloroformate at room temperature to give protected derivatives 15 in almost quantitative yields (Scheme 4, Table 4). The



Scheme 4. Conversion of pyrazolidines 13 into protected pyrazolidines 15 and 18, azaprolines 16 and 17 and protected diamino alcohols 19.

Table 4. Synthesis of pyrazolidines **15** and **18**, azaprolines **16** and protected diamino alcohols **19**.

13 R ¹ R ² 15 (%) ^[a] 16 (%) ^[a] 18 (%) ^[a] 19 (%) ^[a] cis-13a Ph H a (96) a (97) trans-13b Ph TMS b (92) b (90) b (85) b (87) trans-13c Ph CH=CH ₂ c (quant.) c (95) trans-13d 2-furyl TMS d (93) d (63) d (92) d (84)							
cis-13a Ph H a (96) a (97) trans-13b Ph TMS b (92) b (90) b (85) b (87) trans-13c Ph CH=CH ₂ c (quant.) c (95) c trans-13d 2-furyl TMS d (93) d (63) d (92) d (84)	13	\mathbb{R}^1	\mathbb{R}^2	$15 \ (\%)^{[a]}$	16 (%) ^[a]	18 (%) ^[a]	19 (%) ^{[a}
trans-13b Ph TMS b (92) b (90) b (85) b (87) trans-13c Ph CH=CH2 c (quant.) c (95) trans-13d 2-furyl TMS d (93) d (63) d (92) d (84)	cis- 13 a	Ph	Н	a (96)	a (97)		
trans-13c Ph $CH=CH_2$ c (quant.) c (95) trans-13d 2-furyl TMS d (93) d (63) d (92) d (84)	trans-13b	Ph	TMS	b (92)	b (90)	b (85)	b (87)
<i>trans</i> -13d 2-furyl TMS d (93) d (63) d (92) d (84)	trans-13c	Ph	$CH=CH_2$	c (quant.)	c (95)		
	trans-13d	2-furyl	TMS	d (93)	d (63)	d (92)	d (84)

[a] Yields of isolated product.

reaction of **15** with Jones reagent (CrO_3/H^+) led, in very good yields, to azaprolines **16** through an oxidative deprotection of the *tert*-butyldimethylsilyl ether function. On the other hand, pyrazolidine **15c** (R^2 =vinyl) was converted into azaproline **17** (60% yield), analogue of **16**, by oxidative cleavage of the vinyl moiety with the sodium periodate/ruthenium trichloride system; compound **17** keeps the primary hydroxy group in its

structure, which renders it useful for further transformations. It must be pointed out that azaprolines **16** and **17** have been prepared as free carboxylic acids containing orthogonally protected^[30] amino groups; this facilitates their use in peptide synthesis with *N*-terminal amino acids or peptides.

The pyrazolidine ring of compounds 13 makes them potential precursors of 2,4-diamino alcohols by hydrogenolysis of the N-N bond; however, the N2-unprotected 2,4diamino-O-silylated alcohols directly obtained by reductive opening of 13 were unstable to chromatographic purification. Consequently, we transformed the free amino group of 13 successfully into its ethyl carbamate derivative 18 by reaction with ethyl chloroformate (Scheme 4, Table 4). Treatment of 18 with sodium in liquid ammonia gave rise to protected 2,4diamino alcohols 19 in good yields. The structure of compounds 19, containing a γ -diamine and β -amino alcohol unit, allows them to be considered as potential chiral auxiliaries in organic synthesis.^[31] Moreover, compounds 19 should also be, by oxidation of the carbinolic carbon, precursors of γ aminobutyric acid (GABA) derivatives, present as neurotransmitters in mammalians.^[32]

Conclusion

In summary, alkenyl Fischer carbenes derived from (-)-8phenylmenthol have proved to be excellent precursors of enantiomerically pure 3-alkoxycarbonyl- Δ^2 -pyrazolines in a one-pot procedure, the [3+2] cycloaddition between Fischer carbenes and diazoalkanes being the key step. This is the first example of this kind that employs chiral nonracemic alkenyl Fischer carbene complexes. The carbene-metal pentacarbonyl moiety has been found to play a decisive role on the reaction rate and diastereoselectivity. Further, 3-alkoxycarbonyl- Δ^2 -pyrazolines have been demonstrated to be suitable synthons for the preparation of azaprolines, obtained as optimal starting materials for peptide synthesis, and 2,4diamino alcohol derivatives which seem to be appropriate for further synthetic goals.

Experimental Section

General considerations: All reactions involving air-sensitive compounds were carried out under a N2 atmosphere. All common reagents and solvents were obtained from commercial suppliers and used without any further purification unless otherwise indicated. Solvents were dried by standard methods. Hexane, ethyl acetate, and triethylamine were distilled before use. Diazocompounds^[33] were prepared according to published procedures and were used in excess without previous titration. TMSCHN₂ ((CH₃)₃SiCHN₂) was used as a commercially available 2.0м solution in hexane. TLC was performed on aluminum-backed plates coated with silica gel 60 with F254 indicator; the chromatograms were visualized under ultraviolet light and/or by staining with a Ce/Mo reagent (prepared by dissolving phosphomolybdic acid (2 g), cerium(IV) sulfate (1 g), and conc. sulfuric acid (10 mL) in H₂O (90 mL)) and subsequent heating. Flash column chromatography was carried out on silica gel 60, 230-240 mesh. The silica gel used in the purification process of cycloadducts 8 was previously deactivated by treatment with an aqueous solution saturated in potassium hydrogenphosphate and subsequently dried overnight at 120 °C. The enantiomeric purities were determined by chiral HPLC analysis using a Shimadzu instrument on a Chiralcel OD-H (Daicel) column ($25 \times$ 0.46 cm) and detection with photodiode array UV/vis detector. Optical

rotations were determined with a Perkin Elmer 241 polarimeter using a Na lamp; data are reported as follows: $[a]_{D}^{T (^{\circ}C)}$ (concentration in g per 100 mL solvent). Melting points were obtained on a Büchi-Tottoli apparatus with open capillary tubes and are uncorrected. Routine NMR measurements were recorded on Bruker AC-200 or AC-300 spectrometers. ¹H NMR: splitting pattern abbreviations are: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. 13C NMR: multiplicities were determined by DEPT; abbreviations are: q, CH₃; t, CH₂; d, CH; s, quaternary carbons. In the cases where a mixture of diastereomers was observed, the abbreviation min refers to the signals assigned to the minor diastereomer and the abbreviation maj to the signals belonging to the major one; in cases where neither is specified, either it was not possible to assign the signal to any diastereomer or the signal belongs to both of them. NOESY, HMQC, and HMBC experiments were carried out on a Bruker AMX-400 spectrometer. Standard pulse sequences were employed for the DEPT, HMQC, and HMBC experiments. FT-IR spectra were recorded with a Mattson 3000 FT-IR spectrometer. High-resolution mass spectra (HRMS) were obtained with a Finnigan Mat95 mass spectrometer. Elemental analyses were carried out with a Perkin-Elmer 240B microanalyzer.

General procedure for the synthesis of alkenyl carbene complexes 1a-d and 6a-b: The preparation of carbene complexes 1a-b and 6a-b has already been reported.^[20b] Compound 1c was prepared following that methodology, and complex 1d was synthesized according to a slightly modified procedure: tBuLi (112.5 mmol, 1.5 m in pentane) was added through a syringe at -78 °C to a solution of 2-bromopropene (5 mL, 56.2 mmol) in Et₂O (175 mL). The resulting mixture was stirred at the same temperature for 90 min and then slowly added through a cannula to a suspension of [Cr(CO)₆] (13.6 g, 62 mmol) in Et₂O (600 mL). The solution was then stirred at room temperature for an hour, till almost complete disappearance of [Cr(CO)₆] was shown by FT-IR analysis. Solvents were removed under reduced pressure and the remaining solid dissolved in the minimum amount of degassed water (50 mL). The solution was cooled to 0°C and NMe₄Br (10.4 g, 67.5 mmol) was added portionwise and the resulting mixture stirred at the same temperature for 10 min. Water was then removed by means of a cannula, and the resulting orange solid was dried under reduced pressure and then dissolved in CH2Cl2 (500 mL). A solution of pivaloyl chloride (7 mL, 56.2 mmol) in CH2Cl2 (40 mL) was added at -50 °C to the reaction mixture and the resulting solution stirred at this temperature for 45 min. Finally, a solution of (\pm) -menthol (8.9 g, 56.2 mmol) in CH₂Cl₂ (40 mL) was added dropwise at -50° C to the reaction mixture and then allowed to warm to room temperature overnight. Silica gel (10 g) was added to the reaction mixture and solvents were removed under reduced pressure. The resulting residue was purified by column chromatography using as eluent hexane/CH2Cl2: 95/5, yielding 2.70~g~(12~%) of carbone complex $1\,d$ as an orange-red syrup.

Pentacarbonyl[1-((1*R****,2***S****,5***R****)-menthyloxy)-***trans***-3-(4-methoxyphenyl)-2-propenylidene]chromium(0) (1 c): Complex 1 c, a red oil, was prepared following the standard procedure^[20b] in 58 % yield on a 15 mmol scale. R_f=0.23 (hexane); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): \delta= 7.95 -7.65 (brs, 1 H; CH), 7.61 (d, ³***J***(H,H) = 8.6 Hz, 2 H; 2 CH), 7.25 - 6.95 (brs, 1 H; CH), 6.98 (d, ³***J***(H,H) = 8.6 Hz, 2 H; 2 CH), 5.07 (m, 1 H; CH), 3.88 (s, 3H; CH₃), 2.22 - 0.85 (m, 9 H), 1.04 (d, ³***J***(H,H) = 6.6 Hz, 6H; 2 CH₃), 0.90 (d, ³***J***(H,H) = 6.5 Hz, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): \delta = 224.3 (s), 217.1 (s), 162.0 (s), 131.1 (d), 126.9 (s), 114.5 (d), 91.1 (d), 55.2 (q), 48.1 (d), 42.0 (t), 33.9 (t), 31.0 (d), 26.4 (d), 23.8 (t), 21.9 (q), 21.5 (q), 16.9 (q); the signals corresponding to the carbene carbon and the CH of the double bond were not observed; FT-IR (neat): v = 2054 (C=O), 1929 (C=O) cm⁻¹; MS (EI, 70 eV): m/z (%) = 492 (<5) [***M***⁺], 464 (6), 380 (8), 352 (46), 214 (100); HRMS for C₂₅H₂₈CrO₇: calcd 492.1240; found 492.1234; anal. calcd for C₂₅H₂₈CrO₇: C 60.97, H 5.73; found C 61.13, H 5.71.**

Pentacarbonyl[1-((1*R**,2*S**,5*R**)-menthyloxy)-2-methyl-2-propenylidene]chromium(•) (1d): R_f =0.37 (hexane); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 5.25 −4.33 (m, 3H; CH+CH₂), 2.72 −0.71 (m, 21 H); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 351.8 (s), 224.2 (s), 216.3 (s), 154.0 (s), 107.0 (t), 91.7 (d), 47.7 (d), 41.9 (t), 33.6 (t), 31.2 (d), 25.8 (d), 22.8 (t), 21.8 (q), 21.0 (q), 19.3 (q), 16.2 (q); FT-IR (neat): $\bar{\nu}$ = 2062 (C=O), 1932 (C=O) cm⁻¹; MS (EI, 70 eV): m/z (%) = 400 (5) [*M*⁺], 372 (10), 288 (16), 260 (86), 49 (100); HRMS for C₁₉H₂₄CrO₆: calcd 400.0978; found 400.0956; anal. calcd for C₁₉H₂₄CrO₆: C 57.00, H 6.04; found C 56.87, H 6.06. General procedure for the cycloaddition of carbene complexes 1 and 6 with diazomethane derivatives: The corresponding diazocompound (1.5-2 equiv) was added through a syringe to a solution of the carbene complex (1 mmol) in THF (6 mL), and the resulting mixture stirred at RT (or, in the case of diazomethane, at -78 °C) till TLC analysis showed complete disappearance of the starting complex. Then SiO₂ (0.5 g) was added, and solvents removed under reduced pressure. The crude residue was purified by flash column chromatography with hexane/ethyl acetate 20:1 as eluent, yielding the corresponding cycloadducts 2 or 7 as red oils. In the case of carbene complex 1d, the reaction with TMSCHN₂ was carried out at -50 °C and the solution allowed to warm to RT over 4 hours. Then SiO₂ (0.5 g) was added, and solvents were removed under reduced pressure. The crude residue was purified by flash column chromatography using hexane/ ethyl acetate 5:1 as eluent, yielding the tetracarbonylic carbene 4 as a yellow-orange oil.

Pentacarbonyl[(((4R*,5S*)-4,5-dihydro-4-phenyl-5-trimethylsilyl-1H-pyrazol-3-yl)-((1R*,2S*,5R*)-menthyloxy)methylidene]chromium(0) (2a): Yield = 46% (3:1 mixture of diastereomers); $R_f = 0.30$ (hexane/ethyl acetate 20:1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.67$ (brs, 1H; NH, maj), 7.60 (brs, 1H; NH, min), 7.29-7.19 (m, 3H; 3 CH), 7.03-6.98 (m, 2H; 2 CH), 4.84 (m, 1H; CH), 4.16-4.09 (m, 1H; CH), 3.55-3.46 (m, 1H; CH), 2.14-2.08 (m, 1H; CH), 1.74-0.37 (m, 17H), 0.12 (s, 9H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 309.4$ (s), 224.7 (s), 218.0 (s), 160.8 (s), 144.9 (s, min), 144.2 (s, maj), 128.9 (d, maj), 128.6 (d, min), 126.8 (d), 126.6 (d), 126.4 (d), 126.1 (d, maj), 90.1 (d, min), 89.7 (d, maj), 66.6 (d, maj), 65.6 (d, min), 50.8 (d, min), 49.7 (d, maj), 48.2 (d, min), 47.9 (d, maj), 43.5 (t, maj), 41.5 (t, min), 34.0 (t, maj), 33.9 (t, min), 30.8 (d, maj), 30.3 (d, min), 27.3 (d, min), 24.7 (t, min), 24.5 (d, maj), 22.7 (t, maj), 22.2 (q, min), 21.9 (q, maj), 21.7 (q, min), 18.1 (q, min), 16.0 (q, maj), -4.5 (q, maj), -4.6 (q, min); FT-IR (neat): v=3418 (NH), 2050 (C=O), 1931 (C=O), 1402 cm⁻¹; MS (EI, 70 eV): m/z (%) = 576 (<5) [M^+], 436 (<5), 95 (60), 44 (100); anal. calcd for C28H36CrN2O6Si: C 58.32, H 6.29, N 4.86; found C 58.41, H 6.27, N 4.87.

Pentacarbonyl[(((4S*,5S*)-4-(2-furyl)-4,5-dihydro-5-trimethylsilyl-1H-pyrazol-3-yl)- $((1R^*, 2S^*, 5R^*)$ -menthyloxy)methylidene]chromium($\mathbf{0}$) (2b): Yield = 38% (2:1 mixture of diastereomers); $R_f = 0.43$ (hexane/ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.50 (brs, 1 H; NH), 7.27 (m, 1H; CH), 6.27 (m, 1H; CH), 5.91 (m, 1H; CH), 4.94 (m, 1H; CH), 4.25 (m, 1H; CH), 3.57 (m, 1H; CH), 2.26-0.63 (m, 18H), 0.10 (s, 9H; 3 CH_3 ; ${}^{13}\text{C}$ NMR (50 MHz, CDCl₃, 25 °C): $\delta = 311.3$ (s), 224.7 (s), 217.9 (s), 157.9 (s), 155.6 (s, min), 155.4 (s, maj), 141.2 (d, maj), 140.8 (d, min), 110.5 (d), 105.0 (d, min), 104.8 (d, maj), 90.5 (d, min), 89.9 (d, maj), 63.3 (d, maj), 62.4 (d, min), 48.2 (d, min), 48.0 (d, maj), 43.7 (d, min), 43.4 (t, maj), 42.9 (d, maj), 42.2 (t, min), 34.1 (t, min), 34.0 (t, maj), 30.8 (d, maj), 30.6 (d, min), 27.2 (d, min), 24.6 (d, maj), 22.9 (t), 22.1 (q, min), 22.0 (q, maj), 21.9 (q, maj), 21.8 (q, min), 18.0 (q, min), 16.3 (q, maj), -4.4 (q, min), -4.5 (q, maj); FT-IR (neat): $\tilde{v} = 3414$ (NH), 2060 (C=O), 1933 (C=O), 1640 cm⁻¹; MS (EI, 70 eV): m/z (%) = 566 (<5) [M^+], 426 (<5), 119 (78), 49 (100); anal. calcd for C₂₆H₃₄CrN₂O₇Si: C 55.11, H 6.05, N 4.94; found C 55.19, H 6.03, N 4.96.

Pentacarbonyl[((4R*,5S*)-4,5-dihydro-4-(4-methoxyphenyl)-5-trimethylsilyl-1H-pyrazol-3-yl)-((1R*,2S*,5R*)-menthyloxy)methylidene]chromium(0) (2 c): Yield = 40 % (2:1 mixture of diastereomers); $R_f = 0.41$ (hexane/ ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.54 (brs, 1H; NH), 6.95-6.81 (m, 4H; 4 CH), 4.83 (m, 1H; CH), 4.08 (m, 1H; CH), 3.78 (s, 3H; CH₃), 3.41 (m, 1H; CH), 2.29-0.41 (m, 18H), 0.10 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): $\delta = 310.3$ (s, min), 310.1 (s, maj), 224.7 (s), 218.1 (s), 161.4 (s, min), 161.1 (s, maj), 158.4 (s, min), 158.3 (s, maj), 137.3 (s, min), 136.6 (s, maj), 127.8 (d, min), 127.3 (d, maj), 114.3 (d, maj), 114.0 (d, min), 90.1 (d, min), 89.9 (d, maj), 66.6 (d, maj), 65.6 (d, min), 55.3 (q, min), 55.2 (q, maj), 50.0 (d, min), 49.1 (d, maj), 48.3 (d, min), 48.0 (d, maj), 43.5 (t, maj), 41.7 (t, min), 34.0 (t), 30.8 (d, maj), 30.4 (d, min), 27.3 (d, min), 24.8 (t, min), 24.5 (d, maj), 23.0 (t, maj), 22.7 (q, maj), 22.2 (q, min), 21.9 (q, min), 21.8 (q, maj), 18.2 (q, min), 16.1 (q, maj), -4.4 (q, min), -4.5 (q, maj); FT-IR (neat): $\tilde{v} = 3420$ (NH), 3364 (NH), 2050 (C=O), 1925 (C=O), 1611, 1512, 1404 cm $^{-1}$; anal. calcd for $C_{29}H_{38}CrN_2O_7Si\colon C$ 57.41, H 6.31, N 4.62; found C 57.58, H 6.33, N 4.61.

Tetracarbonyl[(4,5-dihydro-5-methyl-1*H*-pyrazol-5-yl)-((1*R**,2*S**,5*R**)menthyloxy)methylidene]chromium(0) (4): Yield = 72% (1:1 mixture of diastereomers); R_f =0.44 (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS, both diastereomers): δ = 7.18 (brs, 1 H; NH), 5.59 (brs, 1 H; CH), 4.98 (m, 1 H; CH), 2.98–2.86 (m, 1 H; CH₂), 2.69–2.59 (m, 1 H;

```
888 —
```

CH₂), 2.37 – 2.31 (m, 1 H), 1.93 – 0.91 (m, 20 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C, both diastereomers): δ = 342.0 (s), 341.8 (s), 232.1 (s), 231.1 (s), 220.5 (s), 220.1 (s), 219.7 (s), 219.2 (s), 152.8 (d), 152.7 (d), 91.5 (d), 91.3 (d), 87.7 (s), 47.2 (d), 46.0 (t), 45.9 (t), 40.7 (t), 40.6 (t), 33.9 (t), 31.3 (d), 26.1 (d), 26.0 (d), 23.0 (t), 22.9 (t), 22.1 (q), 21.2 (q), 21.1 (q), 20.7 (q), 15.84 (q), 15.8 (q); FT-IR (neat): $\vec{\nu}$ = 3169, 2016, 1919, 1852, 1304 cm⁻¹; MS (EI, 70 eV): *m/z* (%) = 414 (7) [*M*⁺], 386 (12), 302 (100), 83 (81); anal. calcd for C₁₉H₂₆CrN₂O₅: C 55.07, H 6.32, N 6.76; found C 54.94, H 6.34, N 6.78.

Pentacarbonyl[((4*R*,5*S*)-4,5-dihydro-4-phenyl-5-trimethylsilyl-1*H*-pyrazol-3-yl)-((1*R*,2*S*,5*R*)-8-phenylmenthyloxy)methylidene]chromium(0) (7b): Yield = 52 % (dr > 95/5); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.68 (brs, 1 H; NH), 7.37 – 7.05 (m, 10 H; 10 CH), 5.32 (m, 1 H; CH), 4.20 (d, ³*J*(H,H) = 5.4 Hz, 1 H; CH), 3.54 (d, ³*J*(H,H) = 5.4 Hz, 1 H; CH), 2.08-1.95 (m, 2 H), 1.53 – 1.49 (m, 2 H), 1.29 (s, 6 H; 2 CH₃), 1.43-0.71 (m, 4 H), 0.90 (d, ³*J*(H,H) = 6.5 Hz, 3 H; CH₃), 0.15 (s, 9 H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 309.5 (s), 224.6 (s), 218.1 (s), 161.1 (s), 1507 (s), 144.6 (s), 129.3 (d), 127.6 (d), 127.1 (d), 126.4 (d), 125.8 (d), 125.2 (d), 90.0 (d), 67.8 (d), 50.7 (d), 49.6 (d), 45.8 (t), 40.8 (s), 33.9 (t), 30.6 (d), 29.7 (q), 26.5 (t), 21.8 (q), 20.8 (q), −4.6 (q); FT-IR (neat): \vec{v} = 3400 (NH), 2050 (C=O), 1917 (C=O) cm⁻¹; anal. calcd for C₃₄H₄₀CrN₂O₆Si: C 62.56, H 6.18, N 4.29; found C 62.63, H 6.17, N 4.30.

Pentacarbonyl[((45,5*R***)-4,5-dihydro-4,5-diphenyl-1***H***-pyrazol-3-yl)-((1***R***,-2***S***,5***R***)-8-phenylmenthyloxy)methylidene]chromium (o) (7c): Yield = 40 % (dr > 95/5); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): \delta = 7.93 (brs, 1 H; NH), 7.43 – 7.01 (m, 15H; 15 CH), 5.40 (m, 1 H; CH), 4.82 (d, ³***J***(H,H) = 4.1 Hz, 1H; CH), 4.17 (d, ³***J***(H,H) = 4.1 Hz, 1H; CH), 2.32 – 0.65 (m, 8 H), 1.30 (s, 6H; 2 CH₃), 0.87 (d, ³***J***(H,H) = 6.5 Hz, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): \delta = 316.5 (s), 224.6 (s), 217.9 (s), 160.3 (s), 150.5 (s), 142.1 (s), 141.0 (s), 129.42 (d), 129.37 (d), 128.9 (d), 128.5 (d), 127.6 (d), 125.7 (d), 126.8 (d), 125.7 (d), 20.8 (q), 20.8 (q), 26.5 (t), 21.7 (q), 20.8 (q); anal. calcd for C₃₇H₃₆CrN₂O₆: C 67.67, H 5.52, N 4.27; found C 67.82, H 5.54, N 4.28.**

Pentacarbonyl[((45,55)-4,5-dihydro-4-phenyl-5-vinyl-1*H*-pyrazol-3-yl)-((1*R*,25,5*R*)-8-phenylmenthyloxy)methylidene]chromium(0) (7d): Yield = 47% (dr > 95/5); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.43 – 7.04 (m, 11H; 10 CH + NH), 5.92 (m, 1H; CH), 5.43 (m, 1H; CH), 5.28 – 5.22 (m, 2H; CH₂), 4.28 (dd, ³*J*(H,H) = 7.8 and 3.5 Hz, 1H; CH), 3.99 (d, ³*J*(H,H) = 3.5 Hz, 1H; CH), 2.34 – 0.67 (m, 8H), 1.32 (s, 6H; 2 CH₃), 0.94 (d, ³*J*(H,H) = 6.0 Hz, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 318.3 (s), 224.6 (s), 217.7 (s), 161.6 (s), 150.5 (s), 140.9 (s), 135.4 (d), 129.3 (d), 127.6 (d), 127.5 (d), 126.9 (d), 125.7 (d), 125.3 (d), 117.1 (t), 91.3 (d), 75.4 (d), 54.7 (d), 50.8 (d), 45.3 (t), 40.8 (s), 33.9 (t), 30.7 (d), 29.9 (q), 26.5 (t), 21.8 (q), 20.8 (q); FT-IR (neat): \vec{v} = 2052 (C=O), 1927 (C=O), 1713 cm⁻¹; anal. calcd for C₃₃H₃₄CrN₂O₆: C 65.34, H 5.65, N 4.62; found C 65.52, H 5.63, N 4.63.

Pentacarbonyl[((45,55)-4-(2-furyl)-4,5-dihydro-5-trimethylsilyl-1*H*-pyrazol-3-yl)-((1*R*,2*S*,5*R*)-8-phenylmenthyloxy)methylidene]chromium(0) (7e): Yield = 53 % (dr > 95/5); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.64 (brs, 1 H; NH), 7.31 – 7.19 (m, 6H; 6 CH), 6.28 (m, 1 H; CH), 6.04 (d, ³*J*(H,H) = 3.0 Hz, 1 H; CH), 5.38 (m, 1 H; CH), 4.35 (d, ³*J*(H,H) = 6.7 Hz, 1 H; CH), 3.64 (d, ³*J*(H,H) = 6.7 Hz, 1 H; CH), 2.31 – 2.05 (m, 4H), 1.64 – 0.72 (m, 4H), 1.37 (s, 3H; CH₃), 0.90 (d, ³*J*(H,H) = 6.0 Hz, 3 H; CH₃), 0.55 (s, 3H; CH₃), 0.14 (s, 9H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 309.5 (s), 224.6 (s), 218.0 (s), 158.1 (s), 155.7 (s), 150.9 (s), 141.3 (d), 127.8 (d), 125.7 (d), 125.3 (d), 110.9 (d), 105.3 (d), 90.3 (d), 64.6 (d), 51.0 (d), 45.6 (t), 42.6 (d), 41.0 (s), 34.0 (t), 30.7 (d), 30.3 (q), 26.7 (t), 21.7 (q), 20.9 (q), −4.5 (q); FT-IR (neat): \tilde{v} = 3415 (NH), 2050 (C=O), 1921 (C=O), 1607, 1402 cm⁻¹; anal. calcd for C₃₂H₃₈CrN₂O₇Si: C 59.80, H 5.96, N 4.36; found C 59.88, H 5.98, N 4.37.

Pentacarbonyl[((4*S*,5*R*)-4-(2-furyl)-4,5-dihydro-5-phenyl-1*H*-pyrazol-3-yl)-((1*R*,2*S*,5*R*)-8-phenylmenthyloxy)methylidene]chromium(0) (7 f): Yield = 42% (dr > 95/5); ¹H NMR (300 MHz, CDCl₃, 25°C, TMS): δ = 7.74 (brs, 1H; NH), 7.44 – 7.04 (m, 11 H; 11 CH), 6.21 (m, 1H; CH), 6.03 (m, 1 H; CH), 5.32 (m, 1 H; CH), 4.80 (d, ³*J*(H,H) = 4.5 Hz, 1H; CH), 4.25 (d, ³*J*(H,H) = 4.5 Hz, 1 H; CH), 2.02-0.55 (m, 8H), 1.25 (s, 3H; CH₃), 0.74 (d, ³*J*(H,H) = 6.5 Hz, 3H; CH₃), 0.43 (s, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25°C): δ = 317.4 (s), 224.6 (s), 217.7 (s), 157.2 (s), 153.4 (s), 150.6 (s), 141.9 (d), 140.2 (s), 129.3 (d), 128.5 (d), 127.8 (d), 125.6 (d), 125.4 (d), 110.9 (d), 106.1 (d), 91.2 (d), 73.9 (d), 50.9 (d), 50.2 (d), 45.1 (t), 40.9 (s), 33.8 (t), 30.6 (d), 30.2 (q), 26.7 (t), 21.7 (q), 20.9 (q); FT-IR (neat): $\bar{\nu}$ = 3410 (NH), 2052 (C=O), 1927 (C=O), 1630 cm^{-1}; anal. calcd for $C_{35}H_{34}CrN_2O_7$: C 65.01, H 5.30, N 4.33; found C 64.88, H 5.31, N 4.31.

Pentacarbonyl[((45,55)-4-(2-furyl)-4,5-dihydro-5-vinyl-1*H*-pyrazol-3-yl)-((1*R*,25,5*R*)-8-phenylmenthyloxy)methylidene]chromium(ø) (7g): Yield = 50% (dr > 95/5); ¹H NMR (300 MHz, CDCl₃, 25°C, TMS): δ = 7.32 – 7.21 (m, 7H; NH + 6 CH), 6.31 (brs, 1H; CH), 6.14 (brs, 1H; CH), 5.92 – 5.79 (m, 1H; CH), 5.45 (m, 1H; CH), 5.28 – 5.24 (m, 2H; CH₂), 4.40 (brs, 1H; CH), 4.22 (brs, 1H; CH), 2.32 – 0.80 (m, 8H), 1.38 (s, 3H; CH₃), 0.92 (d, ³/(H,H) = 6.0 Hz, 3H; CH₃), 0.56 (s, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25°C): δ = 318.1 (s), 224.6 (s), 217.5 (s), 158.5 (s), 152.6 (s), 150.6 (s), 141.7 (d), 134.6 (d), 127.8 (d), 125.6 (d), 125.4 (d), 117.7 (t), 110.9 (d), 106.1 (d), 91.2 (d), 72.6 (d), 51.1 (d), 47.2 (d), 45.2 (t), 40.9 (s), 33.9 (t), 30.7 (d), 30.2 (q), 26.7 (t), 21.7 (q), 20.9 (q); FT-IR (neat): \vec{v} = 3402 (NH), 2054 (C=O), 1997 (C=O), 1599, 1422 cm⁻¹; anal. calcd for C₃₁H₃₂CrN₂O₇: C 62.41, H 5.41, N 4.70; found C 62.57, H 5.42, N 4.69.

General procedure for the protection of cycloadducts 7 with (Boc)₂O: A solution of the corresponding cycloadduct 7 (1 mmol) in CH_2Cl_2 (5 mL) was cooled to -78 °C, and (Boc)_2O (0.45 g, 2 mmol), NEt₃ (0.14 mL, 1 mmol), and DMAP (0.12 g, 1 mmol) successively added. The resulting mixture was stirred at this temperature for 1-2 h, till TLC analysis showed complete disappearance of the starting material. Then, the solvent was removed under reduced pressure and the oily residue purified by flash column chromatography on deactivated silica gel with hexane/ethyl acetate 50/1 as eluent. Thus, oxidation of carbenes 8 to esters 9 was partially prevented and it was possible to isolate *N*-protected cycloadducts 8, as violet syrups, in reasonable yields.

[((4*S*,5*R*)-1-*tert*-Butoxycarbonyl-4,5-dihydro-4-phenyl-5-trimethylsilyl-1-*H*-pyrazol-3-yl)-((1*R*,2*S*,5*R*)-8-phenylmenthyloxy)methylidene]pentacarbonylchromium(0) (8b): Violet syrup over 17 °C; we were able to crystallize it in hexane at -30 °C. Yield = 60 %; ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.52 - 6.89$ (m, 10H; 10 CH), 5.51 (m, 1H; CH), 4.16 (m, 1H; CH), 3.90 (m, 1H; CH), 2.62 - 0.25 (m, 17H), 1.62 (brs, 9H; 3 CH₃), 0.17 (brs, 9H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 325.1$ (s), 225.2 (s), 217.1 (s), 162.8 (s), 151.4 (s), 150.3 (s), 142.8 (s), 129.5 (d), 127.7 (d), 127.7 (d), 125.4 (d), 92.1 (d), 82.7 (s), 64.2 (d), 51.4 (d), 50.7 (d), 45.1 (t), 40.8 (s), 33.8 (t), 30.6 (d), 29.8 (q), 28.1 (q), 26.5 (t), 21.7 (q), 20.9 (q), -2.9 (q); anal. calcd for C₃₉H₄₈CrN₂O₈Si: C 62.22, H 6.43, N 3.72; found C 62.01, H 6.54, N 3.69.

[((45,5*R*)-1-*tert*-Butoxycarbonyl-4,5-dihydro-4,5-diphenyl-1*H*-pyrazol-3-yl)-((1*R*,25,5*R*)-8-phenylmenthyloxy)methylidene]pentacarbonylchromium(**0**) (8 c): Yield = 61 %; ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.26 - 6.75 (m, 15 H; 15 CH), 5.30 (m, 1 H; CH), 4.93 (d, ³*J*(H,H) = 3.5 Hz, 1 H; CH), 3.90 (d, ³*J*(H,H) = 3.5 Hz, 1 H; CH), 2.09 - 0.42 (m, 11 H; 2 CH + 3 CH₂ + CH₃), 1.23 (brs, 9H; 3 CH₃), 1.08 (s, 6H; 2 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 327.1 (s), 225.0 (s), 217.0 (s), 161.7 (s), 150.1 (s), 140.7 (s), 129.6 (d), 129.2 (d), 128.0 (d), 127.9 (d), 59.5 (d), 50.5 (d), 125.6 (d), 124.7 (d), 92.6 (d), 82.9 (s), 74.9 (d), 59.5 (d), 50.5 (d), 44.7 (t), 40.7 (s), 33.7 (t), 30.6 (d), 30.0 (q), 27.9 (q), 26.5 (t), 21.6 (q), 20.9 (q); the signals corresponding to two C (s) around δ = 140 - 150 were not observed; anal. calcd for C₄₂H₄₄CrN₂O₈: C 66.66, H 5.86, N 3.70; found C 66.51, H 5.84, N 3.69.

[((45,55)-1-*tert*-Butoxycarbonyl-4,5-dihydro-4-phenyl-5-vinyl-1*H*-pyrazol-3-yl)-((1*R*,25,5*R*)-8-phenylmenthyloxy)methylidene]pentacarbonylchromium(0) (8 d): Yield = 69 %; ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.42 - 6.97 (m, 10 H; 10 CH), 5.95 - 5.83 (m, 1 H; CH), 5.50 (m, 1 H; CH), 5.28 - 5.20 (m, 2 H; CH₂), 4.65 (m, 1 H; CH), 3.94 (d, ³*J*(H,H) = 3.0 Hz, 1 H; CH), 2.32 - 0.78 (m, 8H), 1.59 (s, 9 H; 3 CH₃), 1.29 (s, 6H; 2 CH₃), 0.92 (d, ³*J*(H,H) = 6.4 Hz, 3 H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 327.4 (s), 225.1 (s), 216.8 (s), 162.6 (s), 150.1 (s), 139.7 (s), 134.1 (d), 129.5 (d), 127.8 (d), 127.7 (d), 126.9 (d), 125.6 (d), 125.4 (d), 116.6 (t), 92.5 (d), 82.9 (s), 72.6 (d), 56.5 (d), 50.7 (d), 44.8 (t), 40.7 (s), 33.8 (t), 30.6 (d), 30.1 (q), 28.1 (q), 26.5 (t), 21.7 (q), 20.9 (q); the signal corresponding to one C (s) around δ = 145 - 150 was not observed; anal. calcd for C₃₈H₄₂CrN₂O₈: C 64.58, H 5.99, N 3.96; found C 64.73, H 6.01, N 3.97.

[((45,55)-1-*tert*-Butoxycarbonyl-4-(2-furyl)-4,5-dihydro-5-vinyl-1*H*-pyrazol-3-yl)-((1*R*,25,5*R*)-8-phenylmenthyloxy)methylidene]pentacarbonyl-chromium(**0**) (8g): Yield = 72 %; ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.32 – 7.17 (m, 6H; 6 CH), 6.34 (m, 1H; CH), 6.15 (d, ³*J*(H,H) = 3.0 Hz, 1H; CH), 5.91 – 5.80 (m, 1H; CH), 5.54 (m, 1H; CH), 5.29 – 5.22 (m, 2H; CH₂), 4.77 (m, 1H; CH), 4.18 (d, ³*J*(H,H) = 3.4 Hz, 1H; CH), 2.30 – 0.75

Chem. Eur. J. 1999, 5, No. 3 © WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1999

0947-6539/99/0503-0889 \$ 17.50+.50/0

FULL PAPER

J. Barluenga et al.

(m, 8 H), 1.58 (s, 9 H; 3 CH₃), 1.35 (s, 3 H; CH₃), 0.91 (d, ³*J*(H,H) = 6.0 Hz, 3 H; CH₃), 0.57 (s, 3 H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 327.6 (s), 225.0 (s), 216.7 (s), 159.7 (s), 151.4 (s), 150.3 (s), 142.2 (d), 133.7 (d), 127.9 (d), 125.6 (d), 125.5 (d), 117.1 (t), 111.0 (d), 106.7 (d), 92.5 (d), 82.9 (s), 69.8 (d), 51.1 (d), 49.1 (d), 44.8 (t), 40.9 (s), 33.9 (t), 30.7 (d), 30.4 (q), 28.1 (q), 26.8 (t), 21.7 (q), 21.0 (q); the signal corresponding to one C (s) around δ = 144 was not observed; FT-IR (neat): \vec{v} = 2060 (C=O), 1942 (C=O), 1599 cm⁻¹; anal. calcd for C₃₆H₄₀CrN₂O₉: C 62.06, H 5.79, N 4.02; found C 61.88, H 5.77, N 4.03.

General procedure for the oxidation of cycloadducts 8 to the corresponding esters 9 with pyridine *N*-oxide: Pyridine *N*-oxide (PNO, 0.19 g, 2 mmol) was added at RT to a solution of carbene complex 8 (1 mmol) in THF (10 mL), and the resulting mixture stirred for 12-24 h, till TLC analysis showed complete disappearance of the starting complex. The solvent was then removed at reduced pressure and the organic residue, once redissolved in hexane/ethyl acetate 3/1 (20 mL), was exposed to sunlight until the organic layer turned completely colorless. The solution was then filtered through Celite and the solvents were removed under vacuum. The oily residue was purified by flash chromatography on silica gel, with hexane/ethyl acetate 50/1, 20/1, and 9/1 as eluent, yielding the corresponding esters 9 as colorless syrups.

(-)-(1*R*,2*S*,5*R*)-8-Phenylmenthyl 3-((4*R*,5*S*)-1-*tert*-butoxycarbonyl-4,5-di-hydro-4-phenyl-5-trimethylsilyl-1*H*-pyrazole)carboxylate (9b): Yield = 75%; [*a*]_D²⁵ = -16.0 (*c* = 1.04 in CHCl₃); R_f =0.55 (hexane/ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.39 – 7.22 (m, 10H; 10 CH), 4.84 (m, 1H; CH), 4.37 (d, ³/(H,H) = 6.0 Hz, 1H; CH), 3.93 (d, ³/(H,H) = 6.0 Hz, 1H; CH), 2.36 – 0.79 (m, 8H), 1.59 (s, 9H; 3 CH₃), 1.31 (s, 3H; CH₃), 1.23 (s, 3H; CH₃), 0.81 (d, ³/(H,H) = 6.1 Hz, 3H; CH₃), 0.20 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 161.1 (s), 151.5 (s), 149.9 (s), 147.9 (s), 141.5 (s), 128.9 (d), 127.8 (d), 127.4 (d), 127.0 (d), 125.7 (d), 125.2 (d), 82.2 (s), 76.5 (d), 60.9 (d), 52.7 (d), 50.3 (d), 41.4 (t), 40.2 (s), 34.2 (t), 31.2 (d), 30.5 (q), 28.1 (q), 27.1 (t), 23.1 (q), 21.5 (q), -2.9 (q); FT-IR (neat): $\dot{\nu}$ =1703 (C=O) cm⁻¹; MS (EI, 70 eV): *m*/z (%) = 576 (< 5) [*M*⁺], 561 (<5), 235 (95), 191 (82), 163 (100); HRMS for C₃₄H₄₈N₂O₄Si: C 70.79, H 8.39, N 4.86; found C 70.86, H 8.41, N 4.84.

(-)-(1*R*,2*S*,5*R*)-8-Phenylmenthyl 3-((4*S*,5*R*)-1-*tert*-butoxycarbonyl-4,5-dihydro-4,5-diphenyl-1*H*-pyrazole)carboxylate (9 c): Yield = 83 %; $[\alpha]_{D}^{25} = -204.0$ (c = 0.97 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.39 - 7.14$ (m, 15 H; 15 CH), 5.17 (m, 1 H; CH), 4.84 (m, 1 H; CH), 4.32 (d, ³*J*(H,H) = 4.7 Hz, 1 H; CH), 1.96 - 0.58 (m, 8 H), 1.33 (brs, 9 H; 3 CH₃), 1.29 (s, 3H; CH₃), 1.23 (s, 3 H; CH₃), 0.79 (d, ³*J*(H,H) = 6.4 Hz, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 160.9$ (s), 150.8 (s), 150.0 (s), 146.9 (s), 141.2 (s), 139.4 (s), 129.2 (d), 129.0 (d), 128.0 (d), 127.8 (d), 50.3 (d), 125.7 (d), 124.9 (d), 82.4 (s), 76.5 (d), 72.8 (d), 60.6 (d), 50.3 (d), 41.5 (t), 40.2 (s), 34.2 (t), 31.2 (d), 29.7 (q), 27.8 (q), 27.1 (t), 24.1 (q), 21.6 (q); MS (EI, 70 eV): *m/z* (%) = 580 (<5) [*M*⁺], 480 (28), 266 (100), 119 (78); HRMS for C₃₇H₄₄N₂O₄: c acd 580.3301; found 580.3309; anal. calcd for C₃₇H₄₄N₂O₄: C 76.52, H 7.64, N 4.82; found C 76.65, H 7.62, N 4.83.

(-)-(1*R*,2*S*,5*R*)-8-Phenylmenthyl 3-((4*S*,5*S*)-1-*tert*-butoxycarbonyl-4,5-di-hydro-4-phenyl-5-vinyl-1*H*-pyrazole)carboxylate (9d): Yield = 86%; $[a]_D^{25} = -103.5 \ (c = 0.95 \ in CHCl_3)$; ¹H NMR (300 MHz, CDCl_3, 25°C, TMS): $\delta = 7.36$ -7.13 (m, 10H; 10 CH), 5.99 – 5.87 (m, 1H; CH), 5.28 – 5.17 (m, 2H; CH₂), 4.85 (m, 1H; CH), 4.66 (m, 1H; CH), 4.16 (d, ³*J*(H,H) = 4.7 Hz, 1H; CH), 1.99 – 0.70 (m, 8H), 1.54 (s, 9H; 3 CH₃), 1.26 (s, 3H; CH₃), 1.21 (s, 3H; CH₃), 0.81 (d, ³*J*(H,H) = 6.5 Hz, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25°C): $\delta = 160.8$ (s), 150.8 (s), 150.1 (s), 147.0 (s), 138.8 (s), 135.0 (d), 129.0 (d), 127.8 (d), 127.1 (d), 125.6 (d), 125.1 (d), 116.6 (t), 82.4 (s), 76.3 (d), 71.0 (d), 57.3 (d), 50.2 (d), 41.4 (t), 40.0 (s), 34.2 (t), 31.2 (d), 28.8 (d), 28.0 (q), 27.0 (t), 24.6 (q), 21.6 (q); MS (EI, 70 eV): *m/z* (%) = 530 (<5) [*M*⁺], 430 (16), 261 (45), 216 (80), 119 (100); HRMS for C₃₃H₄₂N₂O₄: calcd 530.3145; found C 74.78, H 7.99, N 5.27.

(-)-(1*R*,2*S*,5*R*)-8-Phenylmenthyl 3-((4*S*,5*R*)-1-*tert*-butoxycarbonyl-4-(2-furyl)-4,5-dihydro-5-phenyl-1*H*-pyrazol-3-yl)carboxylate (9 f): Yield = 79%; $[\alpha]_{D}^{25} = -132.4$ (c = 0.82 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.35 - 7.06$ (m, 11 H; 11 CH), 6.28 (dd, ³*J*(H,H) = 3.0 and 1.7 Hz, 1 H; CH), 6.09 (d, ³*J*(H,H) = 3.0 Hz, 1 H; CH), 5.22 (d, ³*J*(H,H) = 5.6 Hz, 1 H; CH), 4.79 (m, 1 H; CH), 4.39 (d, ³*J*(H,H) = 5.6 Hz, 1 H; CH), 2.21 - 0.66 (m, 23 H), 0.75 (d, ³*J*(H,H) = 6.5 Hz, 3 H; CH₃); ¹³C NMR

 $\begin{array}{l} (75 \mbox{ MHz, CDCl}_3, 25\ ^{\circ}{\rm C}): \ \delta = 160.7 \ (s), 150.7 \ (s), 150.0 \ (s), 143.6 \ (s), 142.5 \ (d), 140.6 \ (s), 128.9 \ (d), 128.6 \ (d), 127.8 \ (d), 125.7 \ (d), 125.3 \ (d), 125.0 \ (d), 110.7 \ (d), 107.1 \ (d), 82.5 \ (s), 76.7 \ (d), 69.6 \ (d), 53.8 \ (d), 50.3 \ (d), 41.4 \ (t), 40.2 \ (s), 34.3 \ (t), 31.3 \ (d), 29.5 \ (q), 27.8 \ (q), 27.1 \ (t), 24.4 \ (q), 21.6 \ (q); the signal corresponding to one C \ (s) around \ \delta = 150 \ was not observed; MS \ (EI, 70 \ eV): \ m/z \ (\%) = 570 \ (<5) \ [M^+], 470 \ (50), 301 \ (60), 256 \ (100); HRMS \ for C_{35}H_{42}N_2O_5: calcd \ 570.3094; found \ 570.3101; anal. calcd \ for C_{35}H_{42}N_2O_5: C \ 73.66, H \ 7.42, N \ 4.91; found C \ 73.71, H \ 7.44, N \ 4.93. \end{array}$

(-)-(1R,2S,5R)-8-Phenylmenthyl 3-((4S,5S)-1-tert-butoxycarbonyl-4-(2furyl)-4,5-dihydro-5-vinyl-1H-pyrazole)carboxylate (9g): Yield = 87%; $[\alpha]_{D}^{25} = -61.9$ (c = 1.18 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.26$ (d, ${}^{3}J(H,H) = 1.7$ Hz, 1H; CH), 7.19–6.93 (m, 5H; 5 CH), 6.24 (dd, ${}^{3}J(H,H) = 3.4$ and 1.7 Hz, 1H; CH), 6.08 (d, ${}^{3}J(H,H) = 3.4$ Hz, 1H; CH), 5.88-5.76 (m, 1H; CH), 5.21-5.13 (m, 2H; CH₂), 4.80 (m, 1H; CH), 4.70 (m, 1 H; CH), 4.23 (d, ${}^{3}J(H,H) = 5.2$ Hz, 1 H; CH), 2.21-0.68 (m, 8H), 1.45 (s, 9H; 3 CH₃), 1.22 (s, 3H; CH₃), 1.20 (s, 3H; CH₃), 0.75 (d, $^{3}J(H,H) = 6.5 Hz, 3H; CH_{3}); {}^{13}C NMR (75 MHz, CDCl_{3}, 25 °C): \delta = 160.7$ (s), 150.8 (s), 150.4 (s), 150.2 (s), 143.9 (s), 142.4 (d), 134.6 (d), 127.8 (d), 125.7 (d), 125.2 (d), 117.0 (t), 110.7 (d), 107.0 (d), 82.5 (s), 76.5 (d), 68.0 (d), 50.5 (d), 50.3 (d), 41.4 (t), 40.1 (s), 34.3 (t), 31.3 (d), 28.7 (q), 28.1 (q), 27.0 (t), 24.9 (q), 21.6 (q); MS (EI, 70 eV): m/z (%) = 520 (<5) [M^+], 420 (16), 251 (24), 206 (92), 119 (100); HRMS for C₃₁H₄₀N₂O₅: calcd 520.2937; found 520.2960; anal. calcd for $C_{31}H_{40}N_2O_5$: C 71.51, H 7.74, N 5.38; found C 71.47, H 7.77. N 5.39.

General procedure for the one-pot synthesis of esters 9 from carbene complexes 6: The corresponding diazocompound (1.5-2 equiv) was added with a syringe to a solution of the carbene complex 6 (1 mmol) in THF (6 mL), and the resulting mixture stirred at RT (in the case of diazomethane at -78°C) till TLC analysis showed complete disappearance of the starting complex. Then the reaction was cooled to -78 °C, and (Boc)₂O (0.45 g, 2 mmol), NEt₃ (0.14 mL, 1 mmol), and DMAP (0.12 g, 1 mmol) were successively added. The resulting mixture was stirred at this temperature for 1-2 h, till TLC analysis showed complete disappearance of complex 7. Pyridine N-oxide (0.19 g, 2 mmol) was added to the violet solution of carbene complex 8 and the resulting mixture allowed to warm to RT and stirred for an additional 12-24 h, till TLC analysis showed complete disappearance of carbene complex 8. The solvent was removed at reduced pressure and the organic residue, once redissolved in hexane/ethyl acetate 3/1 (20 mL), exposed to sunlight until the organic layer turned completely colorless. The solution was then filtered through Celite and the solvents were removed under vacuum. The oily residue was purified by flash chromatography on silica gel, with hexane/ethyl acetate 50/1, 20/1, and 9/1 as eluents, yielding the corresponding esters 9, greatly improving the overall yield respect to the stepwise procedure.

(-)-(1R,2S,5R)-8-Phenylmenthyl 3-((4S)-1-tert-butoxycarbonyl-4,5-dihydro-4-phenyl-1H-pyrazole)carboxylate (9a): White solid; m.p. = 157-161 °C (hexane); yield = 79% (dr > 95/5); $[\alpha]_D^{25} = -133.0$ (c = 0.99 in CHCl₃); $R_f = 0.22$ (hexane/ethyl acetate 9/1); ¹H NMR (300 MHz, CDCl₃, $25 \degree C$, TMS): $\delta = 7.33 - 7.09$ (m, 10 H; 10 CH), 4.86 (m, 1 H; CH), 4.47 (dd, ${}^{2}J(H,H) = 11.7 \text{ Hz}, {}^{3}J(H,H) = 5.3 \text{ Hz}, 1 \text{ H}; \text{ CH}_{2}, 4.31 \text{ (dd, } {}^{2}J(H,H) = 10.3 \text{ Hz}, 1 \text{ Hz}; 1 \text{ Hz}, 1 \text{ Hz}; 1 \text{$ 11.7 Hz, ${}^{3}J(H,H) = 10.8$ Hz, 1H; CH₂), 3.94 (dd, ${}^{3}J(H,H) = 10.8$ and 5.3 Hz, 1H; CH), 2.11-0.72 (m, 8H), 1.57 (s, 9H; 3 CH₃), 1.26 (s, 3H; CH₃), 1.24 (s, 3H; CH₃), 0.80 (d, ${}^{3}J(H,H) = 5.8$ Hz, 3H; CH₃); ${}^{13}C$ NMR (75 MHz, CDCl₃, 25 °C): $\delta = 160.7$ (s), 151.4 (s), 150.4 (s), 148.3 (s), 139.8 (s), 128.9 (d), 127.8 (d), 127.6 (d), 127.1 (d), 125.6 (d), 124.9 (d), 82.4 (s), 75.9 (d), 56.1 (t), 50.2 (d), 49.7 (d), 41.4 (t), 40.0 (s), 34.2 (t), 31.2 (d), 28.1 (q), 26.9 (t), 25.2 (q), 21.6 (q); the signal corresponding to one C (q) around $\delta =$ 30 was not observed; FT-IR (film): $\tilde{\nu} = 1742$ (C=O), 1705 (C=O), 1148 cm⁻¹; MS (EI, 70 eV): m/z (%) = 504 (<5) [M^+], 190 (80), 119 (100); HRMS for $C_{31}H_{40}N_2O_4$: calcd 504.2988; found 504.2984; anal. calcd for C₃₁H₄₀N₂O₄: C 73.78, H 7.99, N 5.55; found C 73.85, H 8.01, N 5.56.

(+)-(1*R*,2*S*,5*R*)-8-Phenylmenthyl 3-((4*S*,5*S*)-1-*tert*-butoxycarbonyl-4-(2furyl)-4,5-dihydro-5-trimethylsilyl-1*H*-pyrazole)carboxylate (9e): Colorless syrup; yield = 55 % (dr > 95/5); $[\alpha]_D^{25} = +6.3$ (c = 1.05 in CHCl₃); $R_f = 0.61$ (hexane/ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.33 - 7.17$ (m, 6H; 6 CH), 6.32 (dd, ³*J*(H,H) = 3.0 and 1.8 Hz, 1 H; CH), 6.13 (d, ³*J*(H,H) = 3.0 Hz, 1 H; CH), 4.83 (m, 1 H; CH), 4.49 (d, ³*J*(H,H) = 7.5 Hz, 1 H; CH), 3.95 (d, ³*J*(H,H) = 7.5 Hz, 1 H; CH), 2.01 - 0.81 (m, 8 H), 1.56 (s, 9 H; 3 CH₃), 1.31 (s, 6H; 2 CH₃), 0.83 (d, ³*J*(H,H) = 6.2 Hz, 3 H; CH₃), 0.17 (s, 9 H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): $\delta = 161.1$ (s), 152.6 (s), 151.6 (s), 150.0 (s), 144.7 (s), 142.0 (d), 127.8 (d), 125.8 (d), 125.3 (d), 110.6 (d), 106.4 (d), 82.3 (s), 76.7 (d), 57.5 (d), 50.4 (d), 46.1 (d), 41.4 (t), 40.3 (s), 34.3 (t), 31.2 (d), 30.4 (q), 28.1 (q), 27.2 (t), 23.5 (q), 21.6 (q), -2.8 (q); FT-IR (neat): $\vec{\nu} = 1703$ (C=O), 1438 cm⁻¹; MS (EI, 70 eV): m/z (%) = 566 (<5) [M^+], 327 (46), 181 (96), 153 (100); HRMS for C₃₂H₄₆N₂O₅Si: calcd 566.3176; found 566.3176; anal. calcd for C₃₂H₄₆N₂O₅-Si: C 67.81, H 8.18, N 4.94; found C 67.90, H 8.16, N 4.95.

(-)-(1R,2S,5R)-8-Phenylmenthyl 3-((4S)-1-tert-butoxycarbonyl-4-(2-fur**yl)-4,5-dihydro-1***H***-pyrazole)carboxylate** (9h): White solid; m.p. = 49-51 °C (pentane); yield = 74 % (dr = 92/8); $[\alpha]_D^{25} = -65.6$ (c = 1.31 in CHCl₃); $R_f = 0.12$ (hexane/ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS, major diastereomer): $\delta = 7.33 - 7.08$ (m, 6H; 6 CH), 6.32 (dd, ${}^{3}J(H,H) = 3.2$ and 1.8 Hz, 1 H; CH), 6.16 (d, ${}^{3}J(H,H) = 3.2$ Hz, 1 H; CH), 4.92 (m, 1H; CH), 4.60 (dd, ${}^{2}J(H,H) = 11.9$ Hz, ${}^{3}J(H,H) = 6.8$ Hz, 1H; CH_2 , 4.17 (dd, ${}^{2}J(H,H) = 11.9 Hz$, ${}^{3}J(H,H) = 11.3 Hz$, 1H; CH_2), 4.04 (dd, ³*J*(H,H) = 11.3 and 6.8 Hz, 1H; CH), 2.12–0.78 (m, 8H), 1.57 (s, 9H; 3 CH_3 , 1.35 (s, 3H; CH_3), 1.27 (s, 3H; CH_3), 0.85 (d, ${}^{3}J(H,H) = 6.2 Hz$, 3H; CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C, major diastereomer): $\delta = 160.5$ (s), 151.0 (s), 150.3 (s), 144.9 (s), 142.0 (d), 127.7 (d), 125.5 (d), 124.8 (d), 110.5 (d), 106.7 (d), 82.3 (s), 75.9 (d), 52.8 (t), 50.2 (d), 42.9 (d), 41.3 (t), 39.9 (s), 34.2 (t), 31.1 (d), 28.0 (q), 27.7 (q), 26.8 (t), 25.4 (q), 21.5 (q); the signal corresponding to one C (s) around $\delta = 150$ was not observed; FT-IR (film): $\tilde{v} = 1705 \text{ (C=O)}, 1152 \text{ cm}^{-1}; \text{MS (EI, 70 eV)}; m/z (\%) = 494 (<5) [M^+], 438$ (10), 180 (74), 119 (100); HRMS for C₂₉H₃₈N₂O₅: calcd 494.2781; found 494.2781; anal. calcd for $C_{29}H_{38}N_2O_5\colon$ C 70.42, H 7.74, N 5.66; found C 70.55, H 7.72, N 5.67.

Synthesis of cycloadduct 9b starting from cinnamate 10: $TMSCHN_2$ (2.0 M in hexanes, 0.6 mL, 1.2 mmol) was added through a syringe to a solution of cinnamate 10 (0.36 g, 1 mmol) in THF (6 mL) and the resulting mixture stirred over 8 days at 67 °C, till TLC analysis showed complete disappearance of the dipolarophile. The reaction was then cooled to -78 °C and (Boc)₂O (0.45 g, 2 mmol), NEt₃ (0.14 mL, 1 mmol), and DMAP (0.12 g, 1 mmol) were successively added. The solution was allowed to warm to RT and then stirred for 2 h. Solvents were then removed under vacuum and the oily residue purified by flash chromatography on silica gel, with hexane/ethyl acetate 50/1, 20/1 and 9/1 as eluent, yielding the corresponding ester 9b (0.37 g, 65 %) as a mixture of diastereomers (dr = 60/40), that could not be chromatographically separated.

(1*R*,2*S*,5*R*)-8-Phenylmenthyl 3-((4*S*,5*R*)-1-*tert*-butoxycarbonyl-4,5-dihydro-4-phenyl-5-trimethylsilyl-1*H*-pyrazole)carboxylate (9b): Obtained as the minor diastereomer in the reaction of cinnamate 10; R_f =0.55 (hexane/ ethyl acetate 9/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.46 – 7.08 (m, 10H; 10 CH), 4.84 (m, 1 H; CH), 3.84 (m, 2 H; 2 CH), 2.35 – 0.71 (m, 17 H), 1.63 (s, 9 H; 3 CH₃), 0.22 (s, 9 H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 160.5 (s), 152.0 (s), 151.0 (s), 147.8 (s), 142.0 (s), 128.8 (d), 127.9 (d), 127.6 (d), 127.3 (d), 125.8 (d), 125.7 (d), 82.3 (s), 75.9 (d), 60.8 (d), 52.7 (d), 50.3 (d), 40.5 (t), 39.8 (s), 34.3 (t), 31.0 (d), 30.7 (q), 28.2 (q), 26.6 (t), 23.4 (q), 21.6 (q), -2.5 (q).

General procedure for the reduction of esters 9 to alcohols 11: NaBH₄ (0.45 g, 12 mmol) was added at 0 °C to a solution of the corresponding ester 9 (1 mmol) in THF/MeOH (15 mL, 1/1) and the resulting mixture was stirred at RT. After 12 h, more NaBH₄ (0.30 g, 8 mmol) was added and stirring continued for a further 4 h, till TLC analysis showed complete disappearance of the starting material. The reaction was then carefully hydrolyzed at 0 °C with 3 N NaOH (10 mL) and the solvents were removed under vacuum. The aqueous phase was extracted with ethyl acetate (3 × 15 mL) and the combined organic layers dried over Na₂SO₄. After concentration under reduced pressure, the oily residue was purified by flash chromatography on silica gel, with hexane/ethyl acetate 9/1, 5/1 and 3/1 as eluents, yielding the corresponding alcohols 11 as colorless syrups. The chiral auxiliary used in the cycloaddition step was almost quantitatively recovered during the purification process.

(-)-(4S)-1-*tert*-Butoxycarbonyl-4,5-dihydro-3-hydroxymethyl-4-phenyl-1-*H*-pyrazole (11 a): Yield = 83 %; $[\alpha]_D^{21} = -210.6 (c = 0.85 in CHCl_3); R_f = 0.16 (hexane/ethyl acetate 20/1); ¹H NMR (200 MHz, CDCl_3, 25 °C, TMS): <math>\delta = 7.32 - 7.11 (m, 5H; 5 CH), 4.38 (dd, {}^2J(H, H) = 11.8 Hz, {}^3J(H,H) = 6.5 Hz, 1H; CH_2), 4.27 (d, {}^2J(H, H) = 14.3 Hz, 1H; CH_2), 4.17 (dd, {}^2J(H, H) = 11.8 Hz, {}^3J(H,H) = 10.9 Hz, 1H; CH_2), 4.00 (d, {}^2J(H,H) = 14.3 Hz, 1H; CH_2), 3.79 (dd, {}^3J(H,H) = 10.9 and 6.5 Hz, 1H; CH), 1.47 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): <math>\delta = 159.7 (s), 151.9 (s), 138.6 (s), 128.8 (d), 127.3 (d), 127.2 (d), 81.2 (s), 57.7 (t), 54.0 (t), 50.6 (d), 28.0 (q); FT-$ IR (neat): \vec{v} =3414 (OH), 1696 (C=O), 1163 cm⁻¹; MS (EI, 70 eV): m/z(%) = 276 (12) [M^+], 217 (16), 176 (82), 147 (46), 57 (100); anal. calcd for C₁₅H₂₀N₂O₃: C 65.20, H 7.29, N 10.14; found C 65.28, H 7.27, N 10.17.

(-)-(4*R*,5*S*)-1-*tert*-Butoxycarbonyl-4,5-dihydro-3-hydroxymethyl-4-phenyl-5-trimethylsilyl-1*H*-pyrazole (11b): Yield = 81 %; $[a]_D^{25} = -86.0$ (c = 0.79 in CHCl₃); $R_f = 0.65$ (hexane/ethyl acetate 1/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.40 - 7.12$ (m, 5H; 5 CH), 4.30 - 4.07 (ABq, ²*I*(H,H) = 14.9 Hz, 2H; CH₂), 4.13 (d, ³*J*(H,H) = 6.7 Hz, 1H; CH), 3.80 (d, ³*J*(H,H) = 6.7 Hz, 1H; CH), 2.50 (brs, 1H; OH), 1.57 (s, 9H; 3 CH₃), 0.14 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): $\delta = 159.0$ (s), 152.4 (s), 140.4 (s), 129.2 (d), 127.6 (d), 127.2 (d), 81.4 (s), 58.7 (t), 58.4 (d), 54.2 (d), 28.3 (q), -3.0 (q); FT-IR (neat): $\vec{v} = 3418$ (OH), 1694 (C=O) cm⁻¹; MS (EI, 70 eV): m/z (%) = 348 (<5) [M^+], 235 (57), 191 (68), 149 (100); HRMS for C₁₈H₂₈N₂O₃Si: calcd 348.1869; found 348.1869; anal. calcd for C₁₈H₂₈N₂O₃-Si: C 62.03, H 8.10, N 8.04; found C 61.92, H 8.12, N 8.01.

(-)-(4S,5S)-1-*tert*-Butoxycarbonyl-4,5-dihydro-3-hydroxymethyl-4-phenyl-5-vinyl-1*H*-pyrazole (11 c): Yield = quant; $[\alpha]_D^{18} = -168.0$ (c = 1.68 in CHCl₃); $R_f = 0.37$ (hexane/ethyl acetate 1/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.38 - 7.26$ (m, 3 H; 3 CH), 7.14 (d, ³*J*(H,H) = 6.5 Hz, 2 H; 2 CH), 5.89 (ddd, ³*J*(H,H) = 16.7, 10.2, and 7.2 Hz, 1H; CH), 5.17 (m, 2 H; CH₂), 4.61 (dd, ³*J*(H,H) = 6.6 and 5.6 Hz, 1H; CH), 4.32 (d, ²*J*(H,H) = 15.1 Hz, 1H; CH₂), 4.16 (d, ²*J*(H,H) = 15.1 Hz, 1H; CH₂), 4.01 (d, ³*J*(H,H) = 5.1 Hz, 1H; CH), 2.22 (brs, 1H; OH), 1.50 (s, 9H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 158.0$ (s), 151.9 (s), 137.8 (s), 135.7 (d), 129.3 (d), 127.9 (d), 127.4 (d), 116.2 (t), 81.6 (s), 69.6 (d), 58.8 (d), 58.7 (t), 28.2 (q); FT-IR (neat): $\vec{\nu} = 3425$ (OH), 1703 (C=O), 1393, 1367, 1165 cm⁻¹; MS (EI, 70 eV): m/z (%) = 302 (13) [M^+], 243 (15), 202 (58), 57 (100); anal. calcd for C₁₇H₂₂N₂O₃: C 67.53, H 7.33, N 9.26; found C 67.61, H 7.31, N 9.29.

(-)-(4S,5S)-1-*tert*-Butoxycarbonyl-4-(2-furyl)-4,5-dihydro-3-hydroxymethyl-5-trimethylsilyl-1*H*-pyrazole (11 d): Yield = 76%; $[\alpha]_D^{26} = -106.1$ (c = 1.03 in CHCl₃); $R_f = 0.30$ (hexane/ethyl acetate 2/1); ¹H NMR (200 MHz, CDCl₃, 25°C, TMS): $\delta = 7.24$ (m, 1H; CH), 6.20 (dd, ³*J*(H,H) = 3.1 and 1.8 Hz, 1H; CH), 6.04 (d, ³*J*(H,H) = 3.1 Hz, 1H; CH), 4.28 (d, ²*J*(H,H) = 14.3 Hz, 1H; CH₂), 4.26 (d, ³*J*(H,H) = 7.9 Hz, 1H; CH), 4.10 (brs, 1H; OH), 4.04 (d, ²*J*(H,H) = 14.3 Hz, 1H; CH₂), 3.71 (d, ³*J*(H,H) = 7.9 Hz, 1H; CH), 1.42 (s, 9H; 3 CH₃), 0.01 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25°C): $\delta = 156.4$ (s), 152.2 (s), 151.6 (s), 142.0 (d), 110.2 (d), 106.3 (d), 81.0 (s), 57.8 (t), 53.9 (d), 47.0 (d), 27.9 (q), -3.3 (q); FT-IR (neat): $\vec{v} = 3403$ (OH), 1694 (C=O) cm⁻¹; MS (EI, 70 eV): m/z(%) = 338 (<5) [*M*⁺], 267 (17), 181 (79), 139 (96), 73 (89), 57 (100); anal. calcd for C₁₆H₂₆N₂O₄Si: C 56.78, H 7.74, N 8.28; found C 56.69, H 7.72, N 8.31.

General procedure for the protection of alcohols 11 as silyl ethers 12: TBDMSCl (0.23 g, 1.5 mmol) and imidazole (0.14 g, 2 mmol) were successively added at RT to a solution of the corresponding alcohol 11 (1 mmol) in CH₂Cl₂ (5 mL) and the resulting mixture stirred at RT for 1– 2 h, till TLC analysis showed complete disappearance of the starting material. The reaction was hydrolyzed with NaOH 3N (5 mL) and the organic residue extracted with CH₂Cl₂ (3 × 5 mL). The combined organic layers were dried over Na₂SO₄ and solvents removed under vacuum. The oily residue was purified by flash chromatography on silica gel, using as eluent hexane/ethyl acetate 50/1, 20/1 and 9/1, yielding the corresponding silyl ethers 12 as colorless syrups.

(-)-(4S)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4,5-dihydro-4-phenyl-1*H*-pyrazole (12 a): Yield = quant.; $[\alpha]_{D^3}^{25} = -155.3 (c = 1.01)$ in CHCl₃); $R_f = 0.18$ (hexane/ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.27 - 7.08$ (m, 5H; 5 CH), 4.35 (dd, ²*I*(H,H) = 11.7 Hz, ³*I*(H,H) = 6.6 Hz, 1H; CH₂), 4.33 (d, ²*I*(H,H) = 12.8 Hz, 1H; CH₂), 4.17 (dd, ²*I*(H,H) = 11.7 Hz, ³*I*(H,H) = 10.7 Hz, 1H; CH₂), 3.99 (d, ²*I*(H,H) = 12.8 Hz, 1H; CH₂), 3.77 (dd, ³*I*(H,H) = 10.7 and 6.6 Hz, 1H; CH₃), 1.48 (s, 9H; 3 CH₃), 0.76 (s, 9H; 3 CH₃), -0.15 (s, 3H; CH₃), -0.19 (s, 3H; CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): $\delta = 158.9$ (s), 151.8 (s), 138.8 (s), 128.6 (d), 127.3 (d), 127.2 (d), 80.8 (s), 58.5 (t), 53.8 (t), 50.4 (d), 28.0 (q), 25.3 (q), 17.7 (s), -6.1 (q), -6.2 (q); FT-IR (neat): $\vec{v} = 1730$, 1696, 1456, 1433 cm⁻¹; MS (EI, 70 eV): m/z (%) = 390 (<5) [*M*⁺], 333 (13), 277 (100), 233 (41); anal. calcd for C₂₁H₃₄N₂O₃Si: C 64.58, H 8.77, N 7.17; found C 64.49, H 8.79, N 7.19.

Chem. Eur. J. 1999, 5, No. 3 © WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1999 0947-6539/99/0503-0891 \$ 17.50+.50/0

- 891

$$\begin{split} & [a]_D^{25} = -\,49.6 \ (c = 0.98 \ \text{in CHCl}_3); \ R_f = 0.69 \ (\text{hexane/ethyl acetate 3/1}); \\ ^1\text{H NMR (200 MHz, CDCl}_3, 25 ^{\circ}\text{C}, TMS): \ \delta = 7.29 - 7.09 \ (\text{m}, 5\,\text{H}; 5 \ \text{CH}), \\ & 4.35 \ (\text{d}, \, ^2J(\text{H},\text{H}) = 12.8 \ \text{Hz}, 1\,\text{H}; \text{CH}_2), 4.22 \ (\text{d}, \, ^3J(\text{H},\text{H}) = 5.2 \ \text{Hz}, 1\,\text{H}; \text{CH}), \\ & 4.00 \ (\text{d}, \, ^2J(\text{H},\text{H}) = 12.8 \ \text{Hz}, 1\,\text{H}; \text{CH}_2), 3.76 \ (\text{d}, \, ^3J(\text{H},\text{H}) = 5.2 \ \text{Hz}, 1\,\text{H}; \text{CH}), \\ & 1.54 \ (\text{s}, 9\,\text{H}; 3 \ \text{CH}_3), 0.84 \ (\text{s}, 9\,\text{H}; 3 \ \text{CH}_3), 0.12 \ (\text{s}, 9\,\text{H}; 3 \ \text{CH}_3), -0.06 \ (\text{s}, 3\,\text{H}; \\ \text{CH}_3), -0.10 \ (\text{s}, 3\,\text{H}; \text{CH}_3); \, ^{13}\text{C} \,\text{NMR} \ (75 \ \text{MHz}, \text{CDCl}_3, 25 ^{\circ}\text{C}): \ \delta = 159.1 \ (\text{s}), \\ & 152.1 \ (\text{s}), 140.5 \ (\text{s}), 128.7 \ (\text{d}), 127.15 \ (\text{d}), 127.1 \ (\text{d}), 80.8 \ (\text{s}), 58.6 \ (\text{t}), 57.7 \ (\text{d}), \\ & 53.3 \ (\text{d}), 28.1 \ (\text{q}), 25.4 \ (\text{q}), 17.8 \ (\text{s}), -3.2 \ (\text{q}), -5.9 \ (\text{q}), -6.1 \ (\text{q}); \ \text{FT-IR} \\ (\text{neat}): \ \vec{\nu} = 1694 \ (\text{C=O}) \ \text{cm}^{-1}; \,\text{MS} \ (\text{EI}, 70 \ \text{eV}): m/z \ (\%) = 462 \ (<5) \ [M^+], \\ & 405 \ (21), 349 \ (100), 235 \ (70), 206 \ (88), 191 \ (82); \ \text{anal. calcd for} \\ & \text{C}_{24}\text{H}_2\text{N}_2\text{O}_3\text{Si}_2: \ \text{C} \ 62.29, \ \text{H} \ 9.15, \ \text{N} \ 6.05; \ \text{found} \ \text{C} \ 62.34, \ \text{H} \ 9.13, \ \text{N} \ 6.07. \end{split}$$

(-)-(4S,5S)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4,5dihydro-4-phenyl-5-vinyl-1*H*-pyrazole (12 c): Yield = 96 %; $[a]_{15}^{18} = -137.0$ (c = 1.36 in CHCl₃); $R_f = 0.56$ (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.36 - 7.25$ (m, 3H; 3 CH), 7.12 (d, ³*I*(H,H) = 7.0 Hz, 2H; 2 CH), 5.89 (ddd, ³*I*(H,H) = 16.8, 10.2 and 7.2 Hz, 1H; CH), 5.18 (m, 2H; CH₂), 4.57 (dd, ³*J*(H,H) = 7.2 and 5.0 Hz, 1H; CH), 4.40 (d, ²*I*(H,H) = 13.1 Hz, 1H; CH₂), 4.12 (d, ²*I*(H,H) = 13.1 Hz, 1H; CH₂), 4.06 (d, ³*I*(H,H) = 5.0 Hz, 1H; CH), 1.50 (s, 9H; 3 CH₃), 0.81 (s, 9H; 3 CH₃), -0.08 (s, 3H; CH₃), -0.11 (s, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 158.2$ (s), 151.9 (s), 138.2 (s), 135.9 (d), 128.9 (d), 127.6 (d), 127.6 (d), 115.8 (t), 81.3 (s), 69.1 (d), 59.0 (t), 58.4 (d), 28.2 (q), 25.6 (q), 18.0 (s), -5.7 (q), -5.8 (q); FT-IR (neat): v = 1730, 1703, 1365, 1169 cm⁻¹; MS (EI, 70 eV): m/z (%) = 416 (<5) [M^+], 303 (100), 259 (47); anal. calcd for C₂₃H₃₆N₂O₃Si: C 66.31, H 8.71, N 6.72; found C 66.37, H 8.73, N 6.70.

(-)-(4S,5S)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4-(2-furyl)-4,5-dihydro-5-trimethylsilyl-1*H*-pyrazole (12 d): Yield = quant.; $[a]_D^{27} = -32.7$ (c = 0.51 in CHCl₃); $R_f = 0.41$ (hexane/ethyl acetate 9/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.24$ (m, 1H; CH), 6.22 (m, 1H; CH), 6.01 (d, ³*I*(H,H) = 3.1 Hz, 1H; CH), 4.32 (d, ²*I*(H,H) = 12.7 Hz, 1H; CH₂), 4.28 (d, ³*I*(H,H) = 7.6 Hz, 1H; CH), 4.07 (d, ²*I*(H,H) = 12.7 Hz, 1H; CH₂), 3.72 (d, ³*I*(H,H) = 7.6 Hz, 1H; CH), 1.46 (s, 9H; 3 CH₃), 0.04 (s, 9H; 3 CH₃), -0.08 (s, 3H; CH₃), -0.09 (s, 3H; CH₃), ¹³C NMR (50 MHz, CDCl₃, 25 °C): $\delta = 155.6$ (s), 152.13 (s), 152.10 (s), 141.8 (d), 110.2 (d), 106.1 (d), 80.7 (s), 58.8 (t), 54.1 (d), 46.5 (d), 28.0 (q), 25.3 (q), 17.8 (s), -3.2 (q), -5.9 (q), -6.1 (q); FT-IR (neat): v = 1696 (C=O), 1433, 1366, 1252 cm⁻¹; MS (EI, 70 eV): m/z (%) = 452 (<5) [M^+], 395 (10), 339 (100), 181 (53), 73 (69); anal. calcd for C₂₂H₄₀N₂O₄Si₂: C 58.37, H 8.90, N 6.19; found C 58.25, H 8.92, N 6.21.

General procedure for the reduction of silyl ethers 12 to pyrazolidines trans/cis-13: A solution of Superhydride (1.0 m in THF, 2.5 mL, 2.5 mmol) was added dropwise to a solution of the corresponding silyl ether 12 (1 mmol) in the solvent (50 mL) and temperature conditions indicated in Table 3. The resulting mixture was stirred for 12 h, till TLC analysis showed complete disappearance of the starting material (the reduction product was visualized by staining with a Ce/Mo reagent followed by heating). The reaction was then hydrolyzed with 3N NaOH (5 mL) and the organic residue extracted with ethyl acetate (3×15 mL). The combined organic layers were dried over Na2SO4 and solvents removed under vacuum. The oily residue was purified by flash chromatography on silica gel, with hexane/ethyl acetate 20/1, 9/1 and 5/1 as eluents, yielding the corresponding diastereomerically pure pyrazolidines 13 as colorless syrups. Although pyrazolidines 13 can be manipulated in the air, they are moderately unstable and slowly oxidize to silyl ethers 12. In order to prevent their oxidation, they have to be stored under nitrogen at -20 °C. MS spectra and elemental analyses of pyrazolidines 13 could not be recorded because of their decomposition.

(-)-(3*R*,4*S*)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4-phenylpyrazolidine (*cis*-13 a): Yield = 85 % (*trans*-13 a/*cis*-13 a < 5/95; Table 3, entry 1); $[a]_D^{23} = -61.8$ (c = 0.82 in CHCl₃); $R_f = 0.36$ (hexane/ethyl acetate 3/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.36 - 7.17$ (m, 5H; 5 CH), 4.30 (brs, 1H; NH), 3.91 (dd, ²*J*(H,H) = 10.3 Hz, ³*J*(H,H) = 7.1 Hz, 1H; CH₂), 3.72 (dd, ²*J*(H,H) = 10.3 Hz, ³*J*(H,H) = 4.0 Hz, 1H; CH₂), 3.67 (ddd, ³*J*(H,H) = 7.1, 5.6 and 4.0 Hz, 1H; CH), 3.56 (ddd, ³*J*(H,H) = 6.5, 5.6, and 5.2 Hz, 1H; CH), 3.46 (dd, ²*J*(H,H) = 10.1 Hz, ³*J*(H,H) = 5.2 Hz, 1H; CH₂), 3.12 (dd, ²*J*(H,H) = 10.1 Hz, ³*J*(H,H) = 6.5 Hz, 1H; CH₂), 1.52 (s, 9H; 3 CH₃), 0.83 (s, 9H; 3 CH₃), -0.09 (s, 6H; 2 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): $\delta = 154.7$ (s), 138.1 (s), 128.3 (d), 128.0 (d), 126.9 (d), 80.3 (s), 63.5 (d), 60.0 (t), 52.1 (t), 46.9 (d), 28.3 (q), 127 cm⁻¹.

(+)-(35,4*R*,55)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4-phenyl-5-trimethylsilylpyrazolidine (*trans*-13b): Yield = 95 % (*trans*-13b/cis-13b > 95/5; Table 3, entry 2); $[\alpha]_{D}^{25} = +12.9$ (c = 0.28 in CHCl₃); $R_f = 0.59$ (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.32 - 7.18$ (m, 5H; 5 CH), 4.29 (brs, 1H; NH), 3.90 (d, ³*J*(H,H) = 10.5 Hz, 1H; CH₂), 3.67 (d, ³*J*(H,H) = 9.4 Hz, 1H; CH), 3.48-3.41 (m, 2H), 2.94 (m, 1H; CH), 1.52 (s, 9H; 3 CH₃), 0.91 (s, 9H; 3 CH₃), 0.06 (s, 3H; CH₃), 0.04 (s, 3H; CH₃), -0.01 (s, 9H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 156.9$ (s), 141.1 (s), 128.7 (d), 127.9 (d), 126.7 (d), 80.2 (s), 69.4 (d), 58.1 (d), 57.7 (t), 50.9 (d), 28.4 (q), 25.7 (q), 18.2 (s), -2.8 (q), -5.6 (q), -5.7 (q); FT-IR (neat): $\vec{\nu} = 3420$ (NH), 1688 (C=O) cm⁻¹.

(-)-(*3R*,4*S*,5*S*)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4-phenyl-5-vinylpyrazolidine (*cis*-13 c): Yield = 37 % (*trans*-13 c/*cis*-13 c = 50/50; Table 3, entry 4); $[a]_D^{24} = -74.8$ (*c* = 1.32 in CHCl₃); R_f =0.19 (hexane/ethyl acetate 3/1); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.37 - 7.16 (m, 5H; 5 CH), 5.93 (ddd, ³*J*(H,H) = 17.1, 10.1 and 6.6 Hz, 1 H; CH), 5.20 (m, 2 H; CH₂), 4.62 (m, 1 H; CH), 3.67 - 3.62 (m, 1 H; CH), 3.48 - 3.36 (m, 2 H; CH + CH₂), 3.22 (dd, ²*J*(H,H) = 10.0 Hz, ³*J*(H,H) = 5.9 Hz, 1 H; CH₂), 1.50 (s, 9H; 3 CH₃), 0.82 (s, 9H; 3 CH₃), -0.08 (s, 3H; CH₃), -0.09 (s, 3H; CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 153.7 (s), 137.4 (s), 137.2 (d), 128.4 (d), 128.1 (d), 127.0 (d), 115.5 (t), 80.4 (s), 65.4 (d), 61.7 (d), 60.9 (t), 54.0 (d), 28.4 (q), 25.8 (q), 18.1 (s), -5.7 (q); FT-IR (neat): $\tilde{\nu}$ = 3237 (NH), 1707 (C=O), 1366, 1130 cm⁻¹.

(-)-(35,45,55)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4-phenyl-5-vinylpyrazolidine (*trans*-13 c): Yield = 82 % (*trans*-13 c/cis-13 c = 82/18; Table 3, entry 6); $[\alpha]_{2^4}^{2^4} = -4.5$ (c = 1.21 in CHCl₃); $R_f = 0.43$ (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta =$ 7.37 - 7.19 (m, 5H; 5 CH), 5.78 (ddd, ³J(H,H) = 16.9, 10.2 and 6.7 Hz, 1 H; CH), 5.05 - 4.97 (m, 2 H; CH₂), 4.41 (dd, ³J(H,H) = 6.7 and 6.7 Hz, 1 H; CH₂), 3.26 - 3.24 (m, 2 H; 2 CH), 1.48 (s, 9 H; 3 CH₃), 0.90 (s, 9 H; 3 CH₃), 0.03 (s, 3 H; CH₃), 0.02 (s, 3 H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 155.3$ (s), 138.0 (s), 137.2 (d), 128.7 (d), 128.1 (d), 127.2 (d), 115.1 (t), 80.4 (s), 69.9 (d), 67.0 (d), 57.4 (t), 55.3 (d), 28.3 (q), 25.7 (q), 18.1 (s), -5.6 (q), -5.7 (q); FT-IR (neat): v = 1713 (C=O), 1366, 1121 cm⁻¹.

(+)-(35,45,55)-1-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxymethyl-4-(2-furyl)-5-trimethylsilylpyrazolidine (*trans*-13d): Yield = 93 % (*trans*-13d/cis-13d > 95/5; Table 3, entry 7); $[a]_{D}^{21} = +36.0$ (c = 0.84 in CHCl₃); $R_f = 0.55$ (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.29$ (d, ³*J*(H,H) = 1.9 Hz, 1H; CH), 6.26 (dd, ³*J*(H,H) = 3.1 and 1.9 Hz, 1H; CH), 6.04 (d, ³*J*(H,H) = 3.1 Hz, 1H; CH), 4.35 - 4.05 (brs, 1H; NH), 3.95 (dd, ²*J*(H,H) = 10.5 Hz, ³*J*(H,H) = 2.4 Hz, 1H; CH₂), 3.67 (d, ³*J*(H,H) = 9.8 Hz, 1H; CH), 3.65 (dd, ³*J*(H,H) = 10.5 Hz, ³*J*(H,H) = 10.5 Hz, ³*J*(H,H) = 1.3 Hz, 1H; CH₂), 3.54 (dd, ³*J*(H,H) = 9.8 and 9.6 Hz, 1H; CH), 3.02 (ddd, ³*J*(H,H) = 9.6, 2.4 and 1.3 Hz, 1H; CH), 1.47 (s, 9H; 3 CH₃), 0.87 (s, 9H; 3 CH₃), 0.05 - 0.02 (m, 15H; 5 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 156.9$ (s), 153.6 (s), 141.6 (d), 110.0 (d), 105.9 (d), 80.2 (s), 65.4 (d), 58.0 (t), 54.0 (d), 43.7 (d), 28.3 (q), 25.7 (q), 18.2 (s), -3.0 (q), -5.7 (q), -5.8 (q); FT-IR (neat): $\dot{\nu} = 1692$ (C=O), 1468, 1366, 1252, 1167, 1117 cm⁻¹.

General procedure for the synthesis of bicyclic compounds 14: Aqueous saturated K₂CO₂ (12 mL) and CBZCl (0.26 mL, 1.8 mmol) were sequentially added to a solution of the corresponding pyrazolidine 13 (1 mmol) in CH₃CN (2 mL) at room temperature. The resulting mixture was stirred at room temperature for a 1-2 h period, until complete disappearance of the starting material was detected by TLC monitoring (Ce/Mo staining solution). Once the reaction is completed, the organic layer is extracted with ethyl acetate (3×15 mL), dried over Na₂SO₄, and filtered. Solvents were evaporated and the residue was dissolved in dry THF (3 mL) and TBAF (1.5 equiv, 1.36 mL, 1.1m in THF) was added by means of a syringe at 0°C. The reaction was stirred at 0°C for 1.5-2 h till TLC monitoring showed completed disappearance of the CBZ-protected pyrazolidine. Solvents were then evaporated under vacuum and the residue was hydrolyzed with saturated NH4Cl (10 mL) and extracted with Et2O (3 \times 15 mL). The combined organic layers were dried (Na₂SO₄), filtered and vacuum-evaporated, and the residue was purified by flash chromatography over silica gel using hexane/ethyl acetate 20/1 and 9/1 as eluents. Bicyclic carbamates 14 were obtained in the yields described in Scheme 3.

Bicyclic carbamate (±)-14b obtained starting from (±)-*trans*-13b: White solid; m.p. 130–132 °C (hexane); yield = 40 %; R_f =0.38 (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ =7.40–7.24 (m, 5H; 5 CH), 4.49 (dd, ²*J*(H,H) = 9.4 Hz, ³*J*(H,H) = 6.4 Hz, 1H; CH₂), 4.21 (dd, ²*J*(H,H) = 9.4 Hz, ³*J*(H,H) = 1.0 Hz, 1H; CH₂), 3.76 (ddd, ³*J*(H,H) = 9.4 Hz, ³*J*(H,H) = 11.3 Hz, 1H; CH), 3.12 (dd, ³*J*(H,H) = 11.3 and 9.4 Hz, 1H; CH), 1.55 (s, 9H; 3 CH₃), 0.01 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 160.0 (s), 157.1 (s), 136.8 (s), 129.3 (d), 128.1 (d), 127.9 (d), 82.2 (s), 65.1 (t), 64.6 (d), 58.8 (d), 53.9 (d), 28.2 (c), -2.7 (c); anal. calcd for C₁₉H₂₈N₂O₄Si: C 60.61, H 7.50, N 7.44; found C 60.66, H 7.52, N 7.40.

Bicyclic carbamate (±)-14d obtained starting from (±)-*trans*-13d: Colorless syrup; yield = 42 %; R_f =0.54 (hexane/ethyl acetate 3/1); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.39 (m, 1 H; CH), 6.34 (m, 1 H; CH), 6.21 (m, 1 H; CH), 4.57 (dd, ²*J*(H,H) = 9.1 Hz, ³*J*(H,H) = 5.2 Hz, 1 H; CH₂), 4.35 (d, ²*J*(H,H) = 9.1 Hz, 1 H; CH₂), 3.93-3.73 (dd, ³*J*(H,H) = 6.6 and 5.2 Hz, 1 H; CH), 3.76 (d, ³*J*(H,H) = 9.5 Hz, 1 H; CH), 3.27 (dd, ³*J*(H,H) = 9.5 and 6.3 Hz, 1 H; CH), 1.54 (s, 9 H; 3 CH₃), 0.07 (s, 9 H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 159.8 (s), 157.0 (s), 149.9 (s), 142.5 (d), 110.3 (d), 107.4 (d), 82.1 (s), 65.2 (t), 61.5 (d), 55.0 (d), 46.6 (d), 28.0 (c), -3.0 (c); anal. calcd for C₁₇H₂₆N₂O₅Si: C 55.71, H 7.15, N 7.64; found C 55.68, H 7.17, N 7.67.

General procedure for the synthesis of pyrazolidines 15 by treatment of 13 with benzyl chloroformate: Aqueous saturated K_2CO_3 (12 mL) and CBZCl (0.26 mL, 1.8 mmol) were sequentially added to a solution of the corresponding pyrazolidine 13 (1 mmol) in CH₃CN (2 mL) at room temperature. The resulting mixture was stirred at room temperature for 1–2 h, until complete disappearance of the starting material was detected by TLC monitoring (both starting material 13 and product 15 can be visualized by using a Ce/Mo staining solution). Once the reaction is completed, the organic layer is extracted with ethyl acetate (3 × 15 mL), dried over Na₂SO₄, and filtered. Solvents were evaporated and the residue was purified by flash cromatography over silica gel with hexane/ethyl acetate 20/1, 9/1, and 5/1 as eluents. Protected pyrazolidines 15 were obtained in the yields described in Table 4, and they proved to be perfectly air-stable.

(-)-[(3*R*,4*S*)-2-Benzyloxycarbonyl-1-(*tert*-butoxycarbonyl)-3-*tert*-butyldimethylsilyloxymethyl-4-phenylpyrazolidine (15 a): Colorless syrup; yield = 96 %; R_f =0.15 (hexane/ethyl acetate 9/1); $[\alpha]_D^{27}$ = -9.5 (c=0.82 in CHCl₃); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.41 - 7.24 (m, 10H; 10 CH), 5.31 (d, ²*J*(H,H) = 12.3 Hz, 1H; CH₂), 5.19 (d, ²*J*(H,H) = 12.3 Hz, 1H; CH₂), 4.52 (m, 1H; CH), 4.17 - 4.08 (m, 1H), 3.87 - 3.70 (m, 2H), 3.60 (m, 2H), 1.46 (s, 9H; 3 CH₃), 0.79 (s, 9H; 3 CH₃), -0.06 (s, 3H; CH₃), -0.10 (s, 3H; CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 157.4 (s), 155.4 (s), 135.9 (s), 135.8 (s), 128.33 (d), 128.27 (d), 127.9 (d), 127.8 (d), 127.1 (d), 81.1 (s), 67.9 (t), 63.6 (d), 61.5 (t), 51.1 (t), 46.6 (d), 28.0 (c), 25.7 (c), 18.1 (s), -5.9 (c), -6.0 (c); IR (neat): \vec{v} =1703 (C=O), 1701 (C=O), 1366, 1344, 1256, 1163 cm⁻¹; MS (70 eV, EI): *m*/*z* (%) = 526 (< 5) [*M*⁺¹], 426 (55), 369 (29), 91 (100); anal. calcd for C₂₉H₄₂N₂O₅Si: C 66.13, H 8.04, N 5.32; found C 66.18, H 8.01, N 5.29.

(-)-[(3S,4R,5S)-1-Benzyloxycarbonyl-2-(tert-butoxycarbonyl)-5-tert-butyldimethylsilyloxymethyl-4-phenyl-3-trimethylsilylpyrazolidine (15b): Colorless syrup; yield = 92 %; $R_f = 0.47$ (hexane/ethyl acetate 9/1); $[\alpha]_{D}^{24} = -14.4$ (c = 1.40 in CHCl₃); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.40 - 7.24$ (m, 10H; 10 CH), 5.34 (d, ${}^{2}J(H,H) = 12.4$ Hz, 1H; CH₂), 5.20 (d, ${}^{2}J(H,H) = 12.4$ Hz, 1H; CH₂), 4.18 (ddd, ${}^{3}J(H,H) = 6.3$, 4.8 and 4.5 Hz, 1 H; CH), 3.91 (dd, ${}^{2}J(H,H) = 10.0$ Hz, ${}^{3}J(H,H) = 4.8$ Hz, 1 H; CH₂), 3.54 (dd, ${}^{2}J(H,H) = 10.0$ Hz, ${}^{3}J(H,H) = 6.3$ Hz, 1H; CH₂), 3.34 (dd, ${}^{3}J(H,H) = 11.3$ and 4.5 Hz, 1H; CH), 2.85 (d, ${}^{3}J(H,H) = 11.3$ Hz, 1H; CH), 1.43 (s, 9H; 3 CH₃), 0.80 (s, 9H; 3 CH₃), 0.01 (s, 3H; CH₃), -0.02 (s, 3H; CH₃), -0.06 (s, 9 H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 156.4$ (s), 156.1 (s), 140.7 (s), 136.3 (s), 128.4 (d), 128.2 (d), 127.9 (d), 127.6 (d), 126.8 (d), 80.8 (s), 69.7 (d), 64.2 (t), 60.1 (d), 54.0 (d), 27.8 (c), 25.6 (c), 18.0 (s), -0.5 (c), -5.7 (c); IR (neat): $\tilde{\nu} = 1707$ (C=O), 1252 cm^{-1} ; MS (70 eV, EI): m/z (%) = 598 (<5) [M^+], 541 (<5), 498 (42), 91 (100); anal. calcd for C32H50N2O5Si2: C 64.17, H 8.41, N 4.68; found C 64.33, H 8.28, N 4.79.

(-)-[(35,45,55)-1-Benzyloxycarbonyl-2-(*tert*-butoxycarbonyl)-5-*tert*-butyldimethylsilyloxymethyl-4-phenyl-3-vinylpyrazolidine (15 c): Colorless syrup; yield = quant.; R_f =0.30 (hexane/ethyl acetate 9/1); $[\alpha]_D^{22}$ = -17.8 (c = 0.76 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.36-

7.10 (m, 10H; 10 CH), 5.97 (m, 1 H; CH), 5.27-5.05 (m, 4H; 2 CH₂), 4.35-3.66 (m, 4H), 3.41 (m, 1 H), 1.41 (s, 9H; 3 CH₃), 0.83 (s, 9H; 3 CH₃), 0.02 (s, 3H; CH₃), -0.01 (s, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta =$ 154.9 (s), 153.8 (s), 140.1 (s), 135.9 (d), 135.4 (s), 128.7 (d), 128.3 (d), 128.0 (d), 127.6 (d), 127.0 (d), 115.8 (t), 81.5 (s), 70.0 (d), 67.7 (t), 67.3 (d), 62.8 (t), 55.9 (d), 28.0 (c), 25.7 (c), 18.0 (s), -5.6 (c); IR (neat): $\bar{\nu} = 1711$ (C=O), 1142 cm⁻¹; MS (70 eV, EI): m/z (%) = 552 (<5) [M^+], 452 (51), 303 (35), 91 (100); anal. calcd for C₃₁H₄₄N₂O₅Si: C 67.36, H 8.02, N 5.07; found C 67.35, H 7.98, N 5.09.

(-)-[(3S,4S,5S)-1-Benzyloxycarbonyl-2-(*tert*-butoxycarbonyl)-5-*tert*-butyldimethylsilyloxymethyl-4-(2-furyl)-3-trimethylsilylpyrazolidine (15d): White solid; m.p. = 64 – 67 °C (pentane); yield = 93 %; R_f = 0.65 (hexane/ethyl acetate 3/1); $[\alpha]_D^{22} = -26.8 (c = 1.30 \text{ in CHCl}_3)$; ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.47 – 7.26 (m, 6H; 6 CH), 6.30 (dd, ³*J*(H,H) = 3.1 and 1.9 Hz, 1H; CH), 6.12 (dd, ³*J*(H,H) = 3.1 Hz, 1H; CH), 5.32 – 5.19 (m, 2H), 4.25 (m, 1H), 3.93 (m, 1H), 3.60 – 3.49 (m, 2H), 2.98 (d, ³*J*(H,H) = 11.6 Hz, 1H), 1.43 (s, 9H; 3 CH₃), 0.88 (s, 9H; 3 CH₃), 0.06 (s, 3H; CH₃), 0.04 (s, 9H; 3 CH₃), 0.02 (s, 3H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 156.5 (s), 156.1 (s), 152.6 (s), 141.2 (d), 136.3 (s), 128.3 (d), 127.9 (d), 127.7 (d), 110.3 (d), 107.0 (d), 81.1 (s), 67.3 (t), 66.2 (d), 63.8 (t), 56.7 (d), 46.4 (d), 27.9 (c), 25.7 (c), 18.2 (s), -1.0 (c), -5.5 (c), -5.6 (c); IR (film): \vec{v} = 1705 (C=O), 1393, 1252 cm⁻¹; MS (70 eV, EI): *mlz* (%) = 588 (6) [*M*⁺], 517 (9), 488 (82), 91 (100); anal. calcd for C₃₀H₄₈N₂O₆Si₂: C 61.19, H 8.22, N 4.76; found C 61.23, H 8.19, N 4.75.

General procedure for the synthesis of azaprolines 16 by one-pot deprotection-oxidation of pyrazolidines 15: Jones reagent (CrO₃/H⁺, 2 mL, excess) was added dropwise to a solution of the corresponding pyrazolidine 15 (0.15 mmol) at 0 °C until the orange color persisted. The resulting mixture was stirred at room temperature for half an hour; then TLC monitoring indicated complete consumption of 15, so the deprotected alcohol was presumably formed. Stirring was continued until disappearance of the deprotected alcohol was observed by TLC (4 to 10 h) (Compounds 15, 16, and the deprotected alcohol intermediate can be monitored by using a Ce/Mo staining solution). Isopropyl alcohol (3 mL) was then added and solvents were evaporated at low pressure. Ethyl acetate (20 mL) was added to the residue; the resulting suspension was filtered through a pad of Celite and solvents were evaporated under vacuum. The residue was purified by flash cromatography over silica gel, with hexane/ethyl acetate 3/1 and hexane/ethyl acetate/formic acid 20/12/1 as sequential eluents to obtain azaprolines 15 in the yields shown in Table 4.

(-)-3-[(3*R*,4*S*)-2-Benzyloxycarbonyl-1-(*tert*-butoxycarbonyl)-4-phenyl-pyrazolidine] carboxylic acid (16 a): Colorless syrup; yield = 97%; R_f = 0.18 (hexane/ethyl acetate/formic acid 20/12/1); $[a]_D^{28} = -36.3$ (c = 0.53 in CHCl₃); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 8.25 - 7.91 (brs, 1H, COO*H*), 7.42 - 7.11 (m, 10 H; 10 CH), 5.32 - 5.06 (m, 3 H; CH + CH₂), 4.25 - 3.61 (m, 3H; CH + CH₂), 1.42 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 172.5 (s), 156.4 (s), 156.3 (s), 135.4 (s), 134.2 (s), 128.7 (d), 128.4 (d), 128.2 (d), 127.9 (d), 127.8 (d), 82.6 (s), 68.4 (t), 63.8 (d), 52.0 (d), 48.6 (d), 27.9 (c); IR (neat): \vec{v} = 3350 - 2600 (OH), 1740 (C=O), 1724 (C=O), 1713 (C=O), 1155 cm⁻¹; MS (70 eV, EI): m/z (%) = 426 (<5) [*M*⁺], 382 (27), 191 (21), 147 (25), 108 (27), 91 (84), 41 (100); anal. calcd for C₂₃H₂₆N₂O₆: C 64.78, H 6.14, N 6.57; found C 64.75, H 6.18, N 6.62.

(-)-3-[(35,4*R*,5*S*)-2-Benzyloxycarbonyl-1-(*tert*-butoxycarbonyl)-4-phenyl-5-trimethylsilyl pyrazolidine]carboxylic acid (16b): White solid; m.p. 140– 143 °C (CHCl₃); yield = 90 %; R_f = 0.32 (hexane/ethyl acetate/formic acid: 20/12/1); $[\alpha]_{D}^{29}$ = -30.1 (*c* = 1.05 in CHCl₃); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 8.65 (br s, 1 H, COO*H*), 7.40–7.24 (m, 10H; 10 CH), 5.40 (d, ²*J*(H,H) = 12.3 Hz, 1 H; CH₂), 5.20 (d, ²*J*(H,H) = 12.3 Hz, 1 H; CH₂), 4.62 (d, ³*J*(H,H) = 7.6 Hz, 1 H; CH), 3.59 (dd, ³*J*(H,H) = 11.5 and 7.6 Hz, 1 H; CH), 2.87 (d, ³*J*(H,H) = 11.5 Hz, 1 H; CH), 1.40 (s, 9H; 3 CH₃), -0.08 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 173.2 (s), 156.7 (s), 155.8 (s), 137.5 (s), 135.7 (s), 128.9 (d), 128.4 (d), 128.2 (d), 127.9 (d), 82.5 (s), 69.2 (d), 68.2 (t), 60.6 (d), 54.9 (d), 27.6 (c), -0.6 (c); IR (neat): \vec{r} = 3300-2500 (OH), 1723 (C=O), 1713 (C=O) cm⁻¹; MS (70 eV, EI): *m*/*z* (%) = 498 (<5) [*M*⁺¹], 398 (19), 263 (20), 145 (23), 91 (100); anal. calcd for C₂₆H₃₄N₂O₆Si: C 62.63, H 6.87, N 5.62; found C 62.68, H 6.92, N 5.65.

(+)-3-[(35,45,55)-2-Benzyloxycarbonyl-1-(*tert*-butoxycarbonyl)-4-phenyl-5-vinylpyrazolidine]carboxylic acid (16 c): Colorless syrup; yield = 95 %; R_f = 0.30 (hexane/ethyl acetate/formic acid: 20/12/1); [α]_D¹ = +8.8 (c = 0.93 in EtOH); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 9.80-8.90 (brs,

FULL PAPER

1 H, COO*H*), 7.36 – 7.15 (m, 10 H; 10 CH), 6.18 – 5.82 (m, 1 H; CH), 5.41 – 5.03 (m, 4 H; 2 CH₂), 4.71 – 4.31 (m, 2 H; 2 CH), 3.80 – 3.68 (m, 1 H; CH), 1.37 (s, 9 H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 173.2 (s), 155.4 (s), 155.3 (s), 140.0 (s), 135.5 (s), 135.2 (d), 128.9 (d), 128.3 (d), 127.9 (d), 127.5 (d), 126.8 (d), 117.1 (t), 82.5 (s), 69.8 (d), 68.2 (t), 66.3 (d), 56.4 (d), 27.8 (c); IR (neat): $\tilde{\nu}$ = 3400 – 2700 (OH), 1730 (C=O), 1707 (C=O), 1154 cm⁻¹; MS (70 eV, EI): *m/z* (%) = 452 (<5) [*M*⁺], 408 (17), 217 (15), 108 (60), 91 (100); anal. calcd for C₂₅H₂₈N₂O₆: C 66.36, H 6.24, N 6.19; found C 66.33, H 6.20, N 6.23.

(+)-3-[(35,45,55)-2-Benzyloxycarbonyl-1-(*tert*-butoxycarbonyl)-4-(2-furyl)-5-trimethylsilyl pyrazolidine]carboxylic acid (16d): Colorless syrup; yield = 63 %; R_f =0.45 (hexane/ethyl acetate/formic acid 20/12/1); $[a]_{D}^2$ = +5.4 (c = 0.90 in MeOH); ¹H NMR (200 MHz, CDCl₃, 25 °C, TMS): δ = 7.38 – 7.28 (m, 6H; 6 CH), 6.31 (m, 1H; CH), 6.27 (m, 1H; CH), 5.43 (d, ²/(H,H) = 12.5 Hz, 1H; CH₂), 5.16 (d, ²/(H,H) = 12.5 Hz, 1H; CH₂), 4.70 (m, 1H; CH), 3.78 (m, 1H; CH), 2.99 (d, ³/(H,H) = 11.3 Hz, 1H; CH), 1.38 (s, 9H; 3 CH₃), 0.00 (s, 9H; 3 CH₃); ¹³C NMR (50 MHz, CDCl₃, 25 °C): δ = 156.7 (s), 156.1 (s), 149.2 (s), 142.2 (d), 135.6 (s), 128.5 (d), 128.3 (d), 127.9 (d), 110.6 (d), 108.8 (d), 82.8 (s), 68.3 (t), 57.5 (d), 47.8 (d), 27.7 (c), -1.3 (c) (The COOH signal around δ = 173 and another signal for a C (d) around δ = 70 were not detected); IR (neat): \dot{v} =3500 – 2700 (OH), 1717 (C=O), 1152 cm⁻¹; MS (70 eV, EI): m/z (%) = 488 (<5) [M^+], 388 (37), 253 (36), 91 (100); anal. calcd for C₂₄H₃₂N₂O₇Si: C 59.00, H 6.60, N 5.73; found C 59.04, H 6.63, N 5.77.

Synthesis of (-)-3-[(3R,4R,5S)-1-benzyloxycarbonyl-2-(tert-butoxycarbonyl)-5-(tert-butyldimethylsilyloxymethyl)-4-phenylpyrazolidine]carboxylic acid (17) by oxidation of pyrazolidine 15 c: NaIO₄ (130 mg, 0.608 mmol) and RuCl₃ (0.7 mg, 0.02 equiv) were added to a solution of pyrazolidine 15c (82 mg, 0.148 mmol) in CCl₄/CH₃CN/H₂O (0.3/0.3/ 0.45 mL). The resulting mixture was stirred at room temperature for 2.5 h, until disappearance of the starting material was monitored by TLC (both 15c and 17 can be visualized by using a Ce/Mo staining solution). The organic phase was extracted with CH_2Cl_2 (4 × 5 mL), dried over Na_2SO_4 , and filtered through Celite. Solvents were evaporated under vacuum and the residue was purified by flash cromatography over SiO₂, by means of hexane/ethyl acetate 3/1 and hexane/ethyl acetate/formic acid 40/12/1 as sequential eluents, to furnish azaproline 17 (51 mg, 60 %) as a spectroscopically pure white solid. M.p. = 173-5 °C; $R_f = 0.56$ (hexane/ethyl acetate/ formic acid 20/12/1); $[\alpha]_{D}^{24} = -50.6 (c = 0.66 \text{ in EtOH})$; ¹H NMR (300 MHz, $CDCl_3$, 25 °C, TMS): $\delta = 7.35 - 7.11$ (m, 5H; 5 CH), 5.27 - 5.17 (m, 2H; CH₂), 4.61 (m, 1 H), 4.24 (m, 1 H), 3.03 – 2.94 (m, 3 H), 1.47 (s, 9 H; 3 CH₃), 0.92 (s, 9H; 3 CH₃), 0.08 (s, 6H; 2 CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): $\delta = 174.4$ (s), 157.0 (s), 152.1 (s), 140.9 (s), 135.4 (s), 129.1 (d), 128.4 (d), 128.2 (d), 128.1 (d), 127.4 (d), 126.5 (d), 82.4 (s), 68.6 (d), 68.3 (t), 65.9 (d), 62.5 (t), 51.8 (d), 27.9 (c), 25.7 (c), 18.1 (s), -5.6 (c); IR (film): $\tilde{v} = 1738$ (C=O), 1728 (C=O), 1711 (C=O), 1154 cm⁻¹; MS (70 eV, EI): m/z (%) = 570 (<5) [*M*⁺], 470 (12), 413 (15), 367 (13), 256 (22), 203 (15), 91 (100); anal. calcd for C30H42N2O7Si: C 63.13, H 7.42, N 4.91; found C 63.18, H 7.45, N 4.91.

General procedure for the protection of pyrazolidines 13 with ethyl chloroformate: Aqueous saturated K_2CO_3 (1.5 mL) and ClCO₂Et (39 µL, 0.4 mmol) were sequentially added to a solution of pyrazolidine 13 in CH₃CN (2 mL) at room temperature. The resulting mixture was stirred at room temperature for 1–2 h, until complete disappearance of the starting material was detected by TLC monitoring (both starting material 13 and product 18 can be visualized by using a Ce/Mo staining solution). Once the reaction was completed, the organic layer was extracted with ethyl acetate (3 × 5 mL), dried over Na₂SO₄, and filtered. Solvents were evaporated and the residue was purified by flash cromatography over silica gel with hexane/ ethyl acetate 20/1, 9/1, and 5/1 as eluent. Protected pyrazolidines 18 were obtained as colorless syrups in the yields described in Table 4.

(-)-(3*S*,4*R*,5*S*)-1-[(*tert*-Butoxycarbonyl)amino]-3-(*tert*-butyldimethylsilyloxymethyl)-2-(ethoxycarbonyl)-4-phenyl-5-trimethylsilylpyrazolidine (18b): Yield = 85 %; R_f = 0.16 (hexane/ethyl acetate 20/1); $[a]_{20}^{30}$ = -15.6 (*c* = 1.43 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.30 - 7.10 (m, 5H; 5 CH), 4.33 - 4.12 (m, 3H; CH₂ + CH), 3.89 (dd, ²*J*(H,H) = 9.5 Hz, ³*J*(H,H) = 4.7 Hz, 1H; CH₂), 3.51 (dd, ²*J*(H,H) = 9.5 Hz, ³*J*(H,H) = 4.7 Hz, 1H; CH₂), 3.51 (dd, ²*J*(H,H) = 9.5 Hz, ³*J*(H,H) = 11.3 and 6.4 Hz, 1H; CH), 2.83 (d, 1H, ³*J*(H,H) = 11.3 Hz; CH), 1.46 (s, 9H; 3 CH₃), 1.30 (t, ³*J*(H,H) = 7.1 Hz, 3H; CH₃), 0.84 (s, 9H; 3 CH₃), -0.00 (s, 6H; 2 CH₃), -0.10 (s, 9H; 3 CH₃); 1³C NMR (75 MHz, CDCl₃, 25 °C): δ = 156.6 (s), 156.1 (s), 140.9 (s), 128.5

(d), 128.1 (d), 126.8 (d), 80.8 (s), 69.5 (d), 64.3 (t), 61.8 (t), 60.0 (d), 54.1 (d), 28.0 (c), 25.7 (c), 18.1 (s), 14.6 (c), -0.5 (c), -5.6 (c); IR (neat): $\vec{\nu}$ =1705 (C=O) cm⁻¹; MS (70 eV, EI): m/z (%) = 536 (<5) [M^+], 479 (10), 465 (18), 436 (100), 317 (46); anal. calcd for C₂₇H₄₈N₂O₅Si₂: C 60.41, H 8.99, N 5.21; found C 60.42, H 8.98, N 5.24.

(−)-(35,45,55)-1-[(*tert*-Butoxycarbonyl)amino]-3-(*tert*-butyldimethylsilyloxymethyl)-2-(ethoxycarbonyl)-4-(2-furyl)-5-trimethylsilylpyrazolidine (18d): Yield = 92 %; R_f =0.53 (hexane/ethyl acetate 5/1); $[\alpha]_D^{29}$ = -99.6 (c=0.90 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): δ = 7.28 (d, ³/(H,H) = 1.9 Hz, 1H; CH), 6.25 (dd, ³/(H,H) = 3.0 and 1.9 Hz, 1H; CH), 6.07 (d, ³/(H,H) = 3.0 Hz, 1H; CH), 4.26 - 4.12 (m, 3H; CH₂ + CH), 3.88 (dd, ²/(H,H) = 10.2 Hz, ³/(H,H) = 4.4 Hz, 1H; CH₂), 3.55 - 3.43 (m, 2H), 2.91 (d, ³/(H,H) = 11.1 Hz, 1H; CH), 1.43 (s, 9H; 3 CH₃), 1.23 (t, ³/(H,H) = 7.1 Hz, 3H; CH₃), 0.84 (s, 9H; 3 CH₃), 0.02 (s, 3H; CH₃), -0.01 (s, 3H; CH₃), -0.02 (s, 9H; CH₃); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ = 156.4 (s), 156.3 (s), 152.7 (s), 141.2 (d), 110.2 (d), 106.9 (d), 80.8 (s), 66.1 (d), 63.8 (t), 61.8 (t), 46.4 (d), 28.0 (c), 25.7 (c), 18.1 (s), 14.6 (c), -1.1 (c), -5.5 (c); IR (neat): $\bar{\nu}$ = 1732 (C=O), 1705 (C=O) cm⁻¹; MS (70 eV, EI): m/z (%) = 526 (8) [*M*⁺], 469 (13), 455 (27), 426 (100); anal. calcd for C₂₅H₄₆N₂O₆Si₂: C 57.00, H 8.80, N 5.32; found C 57.22, H 8.74, N 5.21.

General procedure for the synthesis of 2,4-diamino alcohols 19 by N–N reduction of pyrazolidines 18: NH₃ was bubbled into a solution of pyrazolidine 18 (0.2 mmol) in THF (10 mL) at -70°C, until aproximately 10 mL were condensed. Excess Na was added and the solution turned dark blue. The resulting mixture was stirred at -40°C for 1 h. Then the reaction was quenched by careful addition of solid NH₄Cl, and NH₃ was allowed to evaporate slowly. The residue was diluted with AcOEt (15 mL) and filtered, and the solvents were evaporated in a rotary evaporator. The resulting residue was purified by flash chromatography over SiO₂, with hexane/ethyl acetate/NEt₃ 20/1/1 as eluent, to give 2,4-diamino alcohols 19 as spectroscopically pure, colorless syrups. Yields are shown in Table 4.

(-)-(2*S*,3*R*,4*S*)-4-[(*tert*-Butoxycarbonyl)amino]-*O*-(*tert*-butyldimethylsilyl)-2-[(ethoxycarbonyl)amino]-3-phenyl-4-trimethylsilyl-1-butanol

(19b): Yield = 87%; $R_f = 0.26$ (hexane/ethyl acetate/triethylamine 20/1/1); $[\alpha]_{D}^{27} = -1.4 (c = 1.20 \text{ in CHCl}_{3}); {}^{1}\text{H NMR} (300 \text{ MHz}, \text{CDCl}_{3}, 25 \,^{\circ}\text{C}, \text{TMS}):$ $\delta = 7.28 - 7.13$ (m, 5H; 5 CH), 5.22 (d, ${}^{3}J(H,H) = 9.5$ Hz, 1H, NH), 4.76 (d, ${}^{3}J(H,H) = 10.6$ Hz, 1H, NH), 4.10 (c, ${}^{3}J(H,H) = 7.1$ Hz, 2H; CH₂), 4.15 – 4.05 (m, 1H; CH), 3.72-3.62 (m, 1H; CH₂), 3.67 (dd, ³J(H,H) = 10.6 and 10.0 Hz, 1H; CH₂), 3.44 (dd, ${}^{2}J(H,H) = 10.0$ Hz, ${}^{3}J(H,H) = 5.9$ Hz, 1H; CH₂), 3.18 (dd, ³*J*(H,H) = 10.0 and 5.9 Hz, 1 H; CH), 1.45 (s, 9 H; 3 CH₃), 1.23 (t, ${}^{3}J(H,H) = 7.1$ Hz, 3H; CH₃), 0.85 (s, 9H; 3 CH₃), -0.02 (s, 3H; $CH_{3}),\;-0.05$ (s, $3\,H;\;CH_{3}),\;-0.24$ (s, $9\,H;\;3\;CH_{3});\;{}^{13}C$ NMR (75 MHz, $CDCl_3$, 25 °C): $\delta = 156.6$ (s), 156.1 (s), 140.2 (s), 128.9 (d), 128.3 (d), 127.0 (d), 79.2 (s), 62.6 (t), 60.6 (t), 54.3 (d), 47.3 (d), 42.5 (d), 28.3 (c), 25.7 (c), 18.0 (s), 14.6 (c), -2.8 (c), -5.6 (c); IR (neat): $\tilde{\nu} = 3437$ (NH), 3333 (NH), 1713 (C=O), 1697 (C=O), 1516, 1507 cm⁻¹; MS (70 eV, EI): m/z (%) = 538 (<5) [*M*⁺], 523 (<5), 481 (10), 425 (35), 392 (57), 246 (100), 146 (88), 73 (93); anal. calcd for $C_{27}H_{50}N_2O_5Si_2$: C 60.18, H 9.35, N 5.20; found C 60.15, H 9.35, N 5.24.

(-)-(2\$,3\$,4\$)-4-[(tert-Butoxycarbonyl)amino]-O-(tert-butyldimethyl-

silyl)-2-[(ethoxycarbonyl)amino]-3-(2-furyl)-4-trimethylsilyl-1-butanol (19d): Yield = 84 %: $R_{\epsilon} = 0.43$ (hexane/ethyl acetate/triethylamine 20/1/1): $[\alpha]_{D}^{26} = -19.6$ (c = 1.38 in CHCl₃); ¹H NMR (300 MHz, CDCl₃, 25 °C, TMS): $\delta = 7.30$ (m, 1 H; CH), 6.26 (m, 1 H; CH), 6.05 (d, ${}^{3}J(H,H) = 2.7$ Hz, 1 H; CH), 5.11 (d, ${}^{3}J(H,H) = 9.0$ Hz, 1 H, NH), 4.63 (d, ${}^{3}J(H,H) = 10.6$ Hz, 1 H, NH), 4.11 - 4.08 (m, 3H; CH + CH₂), 3.70 (dd, ${}^{2}J$ (H,H) = 10.2 Hz, ${}^{3}J(H,H) = 4.4 Hz, 1 H; CH_{2}, 3.61 (dd, {}^{3}J(H,H) = 10.6 and 8.7 Hz, 1 H; CH),$ 3.35 (dd, ${}^{2}J(H,H) = 10.2 \text{ Hz}$, ${}^{3}J(H,H) = 5.7 \text{ Hz}$, 1H; CH₂), 3.26 (dd, ${}^{3}J(H,H) = 8.7$ and 5.8 Hz, 1H; CH), 1.43 (s, 9H; 3 CH₃), 1.23 (t, ${}^{3}J(H,H) = 7.1 \text{ Hz}, 3 \text{ H}; \text{ CH}_{3}), 0.83 \text{ (s, 9 H; 3 CH}_{3}), -0.03 \text{ (s, 3 H; CH}_{3}),$ -0.06 (s, 3H; CH₃), -0.16 (s, 9H; 3 CH₃); ¹³C NMR (75 MHz, CDCl₃, $25 \degree$ C): $\delta = 156.5$ (s), 156.0 (s), 153.0 (s), 141.3 (d), 110.3 (d), 108.3 (d), 79.2 (s), 62.3 (t), 60.6 (t), 52.7 (d), 42.4 (d), 40.9 (d), 28.3 (c), 25.7 (c), 18.0 (s), 14.6 (c), -3.3 (c), -5.65 (c), -5.7 (c); IR (neat): $\tilde{v} = 3443$ (NH), 3439 (NH), 1715 (C=O), 1701 (C=O), 1508, 1250, 1173 cm⁻¹; MS (70 eV, EI): m/z $(\%) = 528 (<5) [M^+], 513 (<5), 471 (10), 415 (21), 382 (39), 246 (84), 146$ (100); anal. calcd for C25H48N2O6Si2: C 56.78, H 9.15, N 5.30; found C 56.69, H 9.10, N 5.32.

Acknowledgments

We are grateful for the financial support received from the Dirección General de Investigación Científica y Técnica (DGICYT, PB92-1005). F.F.M. is indebted to the Ministerio de Educación y Ciencia (Spain) for a predoctoral fellowship.

- [2] For reviews see: a) H.-G. Schmalz, Angew. Chem. 1994, 106, 311; Angew. Chem. Int. Ed. Engl. 1994, 33, 303; b) M. P. Doyle in Comprehensive Organometallic Synthesis II, Vol. 12 (Eds.: E. W. Abbel, F. G. A. Stone, G. Wilkinson), Pergamon, New York, 1995, p. 387; c) W. D. Wulff in ref. [2b], p. 469; d) L. S. Hegedus in ref. [2b], p. 549; e) D. F. Harvey, D. M. Sigano, Chem. Rev. 1996, 96, 271; f) H.-W. Frühauf, Chem. Rev. 1997, 97, 523.
- [3] a) M. P. Doyle, *Chem Rev.* 1986, *86*, 919; b) M. Brookhart, W. B. Studabaker, *Chem. Rev.* 1987, *87*, 411; c) H.-U. Reissig, *Top. Curr. Chem.* 1988, *144*, 73; d) A. Wienand, H.-U. Reissig, *Organometallics* 1990, *9*, 3133; e) C. K. Murray, D. C. Yang, W. D. Wulff, *J. Am. Chem. Soc.* 1990, *112*, 5660; f) J. W. Herndon, S. U. Turner, *J. Org. Chem.* 1991, *56*, 286; g) J. Barluenga, A. Fernández-Acebes, A. A. Trabanco, J. Flórez, *J. Am. Chem. Soc.* 1997, *119*, 7591, and references therein.
- [4] a) K. H. Dötz, Angew. Chem. 1984, 96, 573; Angew. Chem. Int. Ed. Engl. 1984, 23, 587; b) J. S. McCallum, F. A. Kunng, S. R. Gilberston, W. D. Wulff, Organometallics 1988, 7, 2346; c) J. Barluenga, F. Aznar, A. Martín, S. García-Granda, E. Pérez-Carreño, J. Am. Chem. Soc. 1994, 116, 11191; d) R. P. Hsung, J. F. Quinn, B. A. Weisenberg, W. D. Wulff, G. P. A. Yap, A. L. Rheingold, Chem. Commun. 1997, 615 and references therein.
- [5] For leading references, see: a) L. S. Hegedus, S. D'Andrea, J. Org. Chem. 1988, 53, 3113 and references therein; b) L. S. Hegedus, Acc. Chem. Res. 1995, 28, 299; c) J. Zhu, C. Deur, L. S. Hegedus, J. Org. Chem. 1997, 62, 7704.
- [6] For a listing of references in the area see: J. Barluenga, M. Tomás, A. Ballesteros, J. Santamaría, A. Suárez-Sobrino, J. Org. Chem. 1997, 62, 9229.
- [7] a) W. D. Wulff, in Advances in Metal-Organic Chemistry, Vol. 1 (Ed.: L. S. Liebeskind), JAI, Greenwich, 1989; b) K. L. Faron, W. D. Wulff, J. Am. Chem. Soc. 1990, 112, 6419; c) R. Pipoh, R. van Eldik, S. L. B. Wang, W. D. Wulff, Organometallics 1992, 11, 490; d) R. Aumann, K. Roths, M. Läge, B. Krebs, Synlett 1993, 667.
- [8] a) W. D. Wulff, in Comprehensive Organic Synthesis, Vol. 5 (Eds.: B. M. Trost, T. Fleming), Pergamon, New York, 1991, p. 1065; b) W. D. Wulff, W. E. Banta, R. W. Kaesler, P. J. Lankford, R. A. Miller, C. K. Murray, D. C. Yang, J. Am. Chem. Soc. 1990, 112, 3642; c) J. Bao, V. Dragisich, S. Wenglowsky, W. D. Wulff, J. Am. Chem. Soc. 1991, 113, 9873; d) J. Bao, W. D. Wulff, V. Dragisich, S. Wenglowsky, R. G. Ball, J. Am. Chem. Soc. 1994, 116, 7616; e) J. Barluenga, R. M. Canteli, J. Flórez, S. García-Granda, A. Gutiérrez-Rodríguez, J. Am. Chem. Soc. 1994, 6949; f) J. Barluenga, F. Aznar, S. Barluenga, J. Chem. Soc. Chem. Commun. 1995, 1973; g) T. S. Powers, W. Jiang, J. Su, W. D. Wulff, J. Am. Chem. Soc. 1997, 119, 6438; h) J. Barluenga, M. Tomás, J. A. López-Pelegrín, E. Rubio, Tetrahedron Lett. 1997, 38, 3981; i) J. Barluenga, F. Aznar, S. Barluenga, S. García-Granda, C. Alvarez-Rúa, Synlett 1997, 1040; j) J. Barluenga, F. Aznar, M. Fernández, Chem. Eur. J. 1997, 3, 1629; k) J. Barluenga, R. M. Canteli, J. Flórez, S. García-Granda, A. Gutiérrez-Rodríguez, J. Am. Chem. Soc. 1998, 120, 2514 and references therein.
- [9] For reviews, see: a) A. Padwa, in *Comprehensive Organic Synthesis*, *Vol. 4* (Eds.: B. M. Trost, I. Fleming), Pergamon, New York, **1991**, p. 1069; b) P. A. Wade, in ref. [9a], p. 1111; c) R. D. Little, in ref. [9a], *Vol. 5*, p. 239; d) K. V. Gothelf, K. A. Jørgensen, *Chem. Rev.* **1998**, *98*, 863.
- [10] F. R. Kreissl, E. O. Fischer, C. G. Kreiter, J. Organomet. Chem. 1973, 57, C9.
- [11] K. S. Chan, W. D. Wulff, J. Am. Chem. Soc. 1986, 108, 5229.
- [12] a) K. S. Chan, J. Chem. Soc. Perkin Trans 1 1991, 2602; b) K. S. Chan, M. L. Yeung, W. Chan, R.-J. Wang, T. C. W. Mak, J. Org. Chem. 1995, 60, 1741.

- [13] Y. H. Choi, B. S. Kang, Y.-J. Yoon, J. Kin, S. C. Shin, Synth. Commun. 1995, 25, 2043.
- [14] C. Baldoli, P. Del Buttero, E. Licandro, S. Maiorana, A. Papagni, A. Zanotti-Gerosa, J. Organomet. Chem. 1994, 476, C27.
- [15] For a review, see: J. Elguero, in *Comprehensive Heterocyclic Chemistry, Vol. 5* (Eds.: A. R. Katritzky, C. W. Rees), Pergamon, Oxford, **1984**, p. 167.
- [16] a) F. C. Copp, P. J. Islip, J. E. Tateson, *Biochem. Pharmacol.* 1984, *33*, 339; b) J. Frígola, A. Colombo, J. Parés, L. Martínez, R. Sagarra, R. Roser, *Eur. J. Med. Chem.* 1989, *24*, 435.
- [17] For a listing of references in this field, see: A. P. de Silva, H. Q. N. Gunaratne, T. Gunnlaugsson, M. Nieuwenhuizen, *Chem. Commun.* 1996, 1967, and references therein.
- [18] This [1,3] hydrogen shift is quite common in Δ¹-pyrazolines, especially if they bear an electron-withdrawing group at the C3 position. For a recent example of this kind, see: G. Galley, M. Pätzel, P. G. Jones, *Tetrahedron* **1995**, *51*, 1631, and references therein.
- [19] The propensity of silylated Δ¹-pyrazolines of type 5 to lose the silyl group in acidic media has been very recently demonstrated: a) M. R. Mish, F. M. Guerra, E. M. Carreira, J. Am. Chem. Soc. 1997, 119, 8379;
 b) G. A. Whitlock, E. M. Carreira, J. Org. Chem. 1997, 62, 7916.
- [20] a) J. Barluenga, J. M. Montserrat, J. Flórez, S. García-Granda, E. Martín, Angew. Chem. 1994, 106, 1451; Angew. Chem. Int. Ed. Engl. 1994, 33, 1392; b) J. Barluenga, J. M. Montserrat, J. Flórez, S. García-Granda, E. Martín, Chem. Eur. J. 1995, 1, 236; c) J. Barluenga, P. L. Bernard, J. M. Concellón, A. Piñera-Nicolás, S. García-Granda, J. Org. Chem. 1997, 62, 6870.
- [21] For a preliminary communication, see: J. Barluenga, F. Fernández-Marí, A. L. Viado, E. Aguilar, B. Olano, J. Chem. Soc. Perkin Trans. 1 1997, 2267.
- [22] For examples of rate and regioselectivity enhancement of the [(CO)₅Cr] and [(CO)₅W] groups over oxygen in [3+2] cycloadditions, see refs. [11] and [12b].
- [23] J. Elguero, A. Fruchier, J. Chem. Res. Synop. 1990, 200.
- [24] Crystallographic data (excluding structure factors) for the structures 8b and 14b reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publications no. CCDC-102354 and 102355 respectively. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB21EZ, UK (Fax: (+44)1223-336-033; e-mail: deposit@ccdc.cam.ac.uk).
- [25] Crystal data for structures: **Carbene 8b**: Violet crystal, $0.30 \times 0.07 \times 0.07$ mm, monoclinic, space group P_{2_1} , a = 12.79(3), b = 10.42(1), c = 15.71(2) Å, V = 2089(7) Å³, Z = 2, $\rho_x = 1.197$ Mgm⁻³, $\mu = 0.351$ mm⁻¹, F(000) = 7960, T = 293(2) K. Absolute configuration was checked through the Flack parameter, result: $\chi = -0.01(5)$. Final conventional R = 0.072 for 2391 observed reflections and $\omega R2 = 0.227$ (for all reflections) and 504 variables, GoF = 0.98. **Bicyclic carbamate 14b**: Colorless crystal, $0.36 \times 0.20 \times 0.17$ mm, triclinic, space group P1, a = 11.105(6), b = 12.90(1), c = 16.28(1) Å, V = 2157(3) Å³, Z = 4, $\rho_x = 1.159$ Mg m⁻³, $\mu = 0.133$ mm⁻¹, F(000) = 808, T = 293(2) K. Final conventional R = 0.060 for 3211 observed reflections and $\omega R2 = 0.219$ (for all reflections) and 498 variables, GoF = 1.00.
- [26] For a review, see: G. Maas, Top. Curr. Chem. 1987, 137, 75.
- [27] For review, see: a) M. Regitz, H. Heydt, in *1,3-Dipolar Cycloaddition Chemistry* (Ed.: A. Padwa), Wiley, New York, **1984**, p. 393; b) see also ref. [15], p. 254.
- [28] In a very recent case, 5-aminocarbonyl-Δ²-pyrazolines containing a more accessible aldimine type C=N bond were converted into their pyrazolidine derivatives by treatment with NaCNBH₃/AcOH; see ref. [19a].
- [29] At this stage, the enantiomeric purity of compounds **12** was verified by chiral HPLC analysis of derivatives **12b** and **12c** (ee > 98%) on a Chiralcel OD-H column and *n*-hexane/ethanol (400:1) as eluent. This date confirms the high diastereoselectivity observed in the key [3+2] cycloaddition step of the transformation of **6** into **9**.
- [30] P. J. Kocienski, *Protecting Groups* (Eds.: D. Enders, R. Noyori, B. M. Trost), Thieme, New York, **1994**, p. 2.
- [31] For recent reviews on the use of amino alcohols and diamines as chiral auxiliaries, see: a) R. Noyori, M. Kitamura, Angew. Chem. 1991, 103, 34; Angew. Chem. Int. Ed. Engl. 1991, 30, 49; b) K. Soai, S. Niwa, Chem. Rev. 1992, 92, 833; c) H.-U. Blaser, Chem. Rev. 1992, 92, 935;

Chem. Eur. J. 1999, 5, No. 3 © WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1999

0947-6539/99/0503-0895 \$ 17.50+.50/0

 ^[1] E. O. Fischer, A. Maasböl, Angew. Chem. 1964, 76, 571; Angew. Chem. Int. Ed. Engl. 1964, 3, 580.

d) E. N. Jacobsen, in *Catalytic Asymmetric Synthesis* (Ed.: I. Ojima), VCH, Weinheim, **1993**, p. 159.

- [32] For a complete information about GABA derivatives biological activity, see: a) E. Roberts, T. N. Chase, D. B. Tower, GABA in Nervous System Function, Raven, New York, 1976; b) P. Krogsgaard-Larsen, J. Scheel-Kruger, H. Kofod, GABA-Neurotransmitters: Pharmacochemical, Biochemical and Pharmacological Aspects, Munksgaard, Copenhagen, 1979; c) N. G. Bowery, H. Bittiger, H.-R. Olpe, GABA Receptors in Mammalian Function, Wiley, New York, 1990.
- [33] For the preparation of: a) diazomethane from Diazald[®], see: T. H. Black, *Aldrichimica Acta* **1983**, *16*, 3; b) diazoarylderivatives, see: M. Regitz, *Diazoalkanes*, Thieme, Stuttgart, **1977** p. 121; c) 3-diazopropene, see: R. G. Salomon, M. F. Salomon, T. R. Heyne, *J. Org. Chem.* **1975**, *40*, 756.

Received: 30 July 1998 [F1274]